HALF THE COUNTRY, ZERO HEARINGS: MEETING THE MOMENT TO END THE MENOPAUSE CARE GAP IN AMERICA

Special Committee on Aging Senate September 16, 2026

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

- HALF THE COUNTRY, ZERO HEARINGS: MEETING THE MOMENT TO END THE MENOPAUSE CARE GAP IN AMERICA

[Senate Hearing 119-545]
[From the U.S. Government Publishing Office]

 S. Hrg. 119-545

 HALF THE COUNTRY, ZERO HEARINGS:
 MEETING THE MOMENT TO END THE
 MENOPAUSE CARE GAP IN AMERICA
=======================================================================

 HEARING

 BEFORE THE

 SPECIAL COMMITTEE ON AGING

 UNITED STATES SENATE

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 __________

 WASHINGTON, DC

 __________

 SEPTEMBER 16, 2026

 __________

 Serial No. 119-35

 Printed for the use of the Special Committee on Aging
 
[GRAPHIC NOT AVAILABLE IN TIFF FORMAT] 

 Available via the World Wide Web: http://www.govinfo.gov
 
 __________
 
 U.S. GOVERNMENT PUBLISHING OFFICE 
65-552 PDF WASHINGTON : 2026
=======================================================================
 
 SPECIAL COMMITTEE ON AGING

 RICK SCOTT, Florida, Chairman

DAVE McCORMICK, Pennsylvania KIRSTEN E. GILLIBRAND, New York
JIM JUSTICE, West Virginia ELIZABETH WARREN, Massachusetts
TOMMY TUBERVILLE, Alabama MARK KELLY, Arizona
RON JOHNSON, Wisconsin RAPHAEL WARNOCK, Georgia
ASHLEY MOODY, Florida ANDY KIM, New Jersey
JON HUSTED, Ohio ANGELA ALSOBROOKS, Maryland
 ---------- 
 McKinley Lewis, Majority Staff Director
 Claire Descamps, Minority Staff Director
 
 
 C O N T E N T S

 ---------- 

 Page

Opening Statement of Senator Kirsten E. Gillibrand, Ranking 
 Member......................................................... 1
Opening Statement of Senator Rick Scott, Chairman................ 2

 PANEL OF WITNESSES

Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished 
 Professor, School of Public Health and Health Professions, 
 University at Buffalo, Buffalo, New York....................... 4
Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, 
 American College of Obstetricians and Gynecologists, Pittston, 
 Pennsylvania................................................... 6
Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's 
 Leadership Center at NYU Law, New York, New York............... 8
Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board-
 Certified Gynecologist, Founder, TaraMD, Women's Health 
 Ambassador, HHS Office on Women's Health, New York, New York... 10

 APPENDIX
 Prepared Witness Statements

Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished 
 Professor, School of Public Health and Health Professions, 
 University at Buffalo, Buffalo, New York....................... 28
Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, 
 American College of Obstetricians and Gynecologists, Pittston, 
 Pennsylvania................................................... 33
Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's 
 Leadership Center at NYU Law, New York, New York............... 35
Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board-
 Certified Gynecologist, Founder, TaraMD, Women's Health 
 Ambassador, HHS Office on Women's Health, New York, New York... 53

 Questions for the Record

Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished 
 Professor, School of Public Health and Health Professions, 
 University at Buffalo, Buffalo, New York....................... 59
Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, 
 American College of Obstetricians and Gynecologists, Pittston, 
 Pennsylvania................................................... 72
Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's 
 Leadership Center at NYU Law, New York, New York............... 76
Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board-
 Certified Gynecologist, Founder, TaraMD, Women's Health 
 Ambassador, HHS Office on Women's Health, New York, New York... 79

 Statements for the Record

51& Statement.................................................... 84
American Academy of Family Physicians Statement.................. 89
ABIG Health Statement............................................ 92
American College of Obstetricians and Gynecologists Statement.... 118
Marion Adams Statement........................................... 124
Andrea Giancontieri Statement.................................... 132
Gia Thomas Statement............................................. 137
Hadassah Menopause Statement..................................... 141
Let's Talk Menopause Statement................................... 144
 C O N T E N T S

 ---------- 

 Statements for the Record (cont'd)

 Page

Liz Powell Statement............................................. 146
New York University Grossman School of Medicinie Statement....... 149
National Menopause Foundation Statement.......................... 152
Kimberly Paine Statement......................................... 158
Sharon Carothers Statement....................................... 164
The Pause Life's Statement....................................... 172

 
 HALF THE COUNTRY, ZERO HEARINGS:
 MEETING THE MOMENT TO END THE
 MENOPAUSE CARE GAP IN AMERICA

 ---------- 

 Wednesday, September 16, 2026

 U.S. Senate
 Special Committee on Aging
 Washington, DC.
 The Committee met, pursuant to notice, at 3:27 p.m., Room 
216, Hart Senate Office Building, Hon. Rick Scott, Chairman of 
the Committee, presiding.
 Present: Senator Scott, Moody, Gillibrand, and Kim.
 The Chairman. The Special Committee on Aging will now come 
to order. As Chairman, I am proud of this Committee's long 
history of working together on a bipartisan basis to address 
topics that impact aging Americans.
 Today, we continue this tradition with Ranking Member 
Gillibrand chairing the first ever congressional hearing 
focused on menopause. I now recognize Ranking Member Gillibrand 
for her opening statement.

 OPENING STATEMENT OF SENATOR 
 KIRSTEN E. GILLIBRAND, RANKING MEMBER

 Senator Gillibrand. Thank you, Mr. Chairman, for giving me 
the opportunity and the opportunity for all of us to have this 
hearing. I am super excited. It is one of the most under-
researched, under-treated, and under-discussed topics.
 We call it the menopause care gap and thank you to the 
witnesses for sharing your experiences and expertise today. We 
are very excited to hear from you. Seventy-five million 
American women are in perimenopause, menopause, or post-
menopause right now. Congress has never held a single hearing 
on the gaps in care that they face, and that changes today. 
Menopause affects half the population. For generations, women 
have been told to suffer in silence. I am done with silence.
 Menopause affects half of the population, and this is 
something that we have to address. The neglect of menopause 
research, education, and treatment is a health care failure, an 
economic failure, and a policy failure. While medical education 
continues to evolve, previous studies have shown 80 percent of 
OBGYN residents say they are unprepared to talk about 
menopause.
 Eighty percent of the doctors that are supposed to be the 
most knowledgeable say they are unprepared to talk about 
menopause. Fewer than one-third of residency programs teach it 
at all. Three out of four women who seek care for symptoms 
leave untreated.
 That is unacceptable. We have made great advances in 
treating symptoms, but access remains a significant barrier. 
Whether it be misleading labels, insurance not covering it, or 
patch shortages, it is clear women are not getting the care 
that they need. The cost is enormous for women and the economy.
 The Mayo Clinic puts the price of menopause in the United 
States at $26.6 billion per year. $1.8 billion of that is lost 
work time alone. As many as one in ten women leave the 
workforce because of menopause. They walk out at the peak of 
their careers and take decades of knowledge and experience with 
them. It is a tragedy, and it is avoidable and the Federal 
Government has never adequately funded the research that could 
fix it.
 We need a comprehensive strategy to prioritize midlife 
women's health in research, like the one in the bipartisan bill 
that Senators Murray and Murkowski lead. Research is the 
foundation. It drives clinician training, better information, 
and evidence-based treatment for patients.
 We also have to make sure women can actually get in the 
door. The average wait time to see an OBGYN in this country is 
over a month. In rural communities, it is longer. For women who 
have been experiencing debilitating pain, heavy bleeding, and 
symptoms she can't explain, a month is far too long. We must 
strengthen this workforce facing critical shortages and make 
sure it is ready when patients arrive.
 To do that, we need to know where to start. I am proud to 
lead a bipartisan request to the Government Accountability 
Office alongside Chairman Scott, and members of this Committee. 
It will tell us what the Federal Government actually does on 
menopause, how well our doctors are trained, and where the gaps 
are.
 You can't fix what you refuse to even measure. Women have 
carried this alone for generations. Not anymore. We must meet 
the moment, and I look forward to hearing from our witnesses 
today and discussing this critical issue.

 OPENING STATEMENT OF SENATOR 
 RICK SCOTT, CHAIRMAN

 The Chairman. Thank you, Ranking Member. Thank you for your 
leadership on this issue. Women make up half of the American 
population, and eight to ten million Americans experience 
menopausal symptoms each year.
 While menopause is a natural part of aging for women, every 
woman is impacted differently and more often than not, they are 
not simply dealing with a minor inconvenience. They are facing 
symptoms that have real consequences on their quality of life. 
Not to mention having to navigate finding a doctor, 
understanding their symptoms, developing a treatment plan, and 
managing changes to their health, all while balancing jobs, 
families, and everything else life throws at them.
 That is unacceptable. Women should not suffer in silence. 
Too often, women still enter this stage of their lives without 
the information they need or clear understanding of what to 
expect and then they are focused--they are forced to figure out 
as they go through it. There is simply no excuse for the lack 
of resources and information to help every woman navigate 
menopause and the challenges that come with it.
 The hearing is not about a one-size fits all solution. It 
is about ensuring that every woman in this country has access 
to good information, the right health care provider, and 
treatment options, so they can advocate for themselves and make 
the best decisions for their health.
 To empower women with information so they can be the best 
advocates for their help, we must first identify the gaps. That 
is why I am proud to work with Ranking Member Gillibrand on a 
letter to the GAO asking them to identify gaps in menopause 
research and care. We also need providers who have most up to 
date training, who are able to clearly discuss treatment 
options with their patients.
 Right now, women have several treatment options at their 
disposal to manage symptoms, including hormone replacement 
therapy. For years, however, questions and concerns about the 
safety of hormone therapy and the FDA's black box warning on 
these products left women and doctors unsure how to proceed.
 Thankfully, we now know that hormone replacement therapy is 
a safe option for many women. Still, access barriers like lack 
of information and limited availability can make it difficult 
for women to access these medications. I applaud the FDA for 
improving access to menopausal treatment by taking steps like 
removing the black box warning on hormone replacement therapy 
treatments and empowering women to make the best decision for 
themselves and their health.
 Following the FDA's removal of the black box warning last 
November, the data is already showing that women are using 
treatments like hormone replacement therapies and estrogen 
patches more. Treatment is a huge piece of the puzzle, but the 
shortage of health care providers creates barriers to accessing 
it in the first place. There are simply not enough specialists 
to meet the growing demand.
 Approximately two million women enter menopause each year, 
and the number of residents and physicians is not keeping pace 
with the aging population. These shortages result in a lack of 
access and physician burnout. The doctors we have are facing 
tremendous pressure.
 More than 45 percent of OBGYNs have reported experiencing 
burnouts. Just earlier this year, this Committee had a hearing 
where we heard firsthand about this happening. Congress should 
look at what we can do to eliminate unnecessary regulatory 
barriers and administrative burdens that take doctors away from 
the patients and contribute to burnout. Every woman has a 
difficult journey--has a different journey, and difficult--with 
menopause, and menopausal can have a wide range of effects, 
which is why it is so important that women have access to 
providers and treatment.
 Changes in hormone levels associated with menopause can 
affect bone, heart, and other aspects of women's health, and 
appropriate treatments can make a real difference in women's 
symptoms and quality of life. Hormone replacement therapy not 
only helps women manage their menopause symptoms but can also 
improve their quality of life post-menopause.
 America has incredible doctors, nurses, researchers, and 
treatments. Our job should be to make sure women know what 
options are available, have good information, and can get the 
care they need. Today's hearing is an important first step in 
how we talk about menopause and women's health in Congress.
 I am proud to bring awareness to it with the members of the 
Committee. I want to again thank my colleague and Ranking 
Member, Gillibrand, for leading on this issue. This affects so 
many Americans and I look forward to today's discussion. I 
think I will turn it back to Ranking Member Gillibrand and she 
will introduce our first three witnesses.
 Senator Gillibrand. Thank you, Mr. Chairman. Our first 
witness, is Dr. Jean Wactawski-Wende.
 Dr. Wactawski-Wende is the Dean and SUNY Distinguished 
Professor at the School of Public Health and Health Professions 
at the University at Buffalo. There she leads the Women's 
Health Initiative Northeast Regional Center and conducts 
research on factors influencing women's health.
 Previously, she served as the Chair of the WHO Steering 
Committee and has served as Principal Investigator on dozens of 
NIH funded research studies. She brings 40 years of experience 
in women's health research to our discussion today. You may 
begin.

 STATEMENT OF JEAN WACTAWSKI-WENDE, PH.D,

 DEAN AND SUNY DISTINGUISHED PROFESSOR, SCHOOL

 OF PUBLIC HEALTH AND HEALTH PROFESSIONS, UNIVERSITY

 AT BUFFALO, BUFFALO, NEW YORK

 Dr. Wactawski-Wende. [Technical problems] Chairman Scott, 
Ranking Member Gillibrand, and honorable members of the Senate 
Special Committee on Aging, thank you for this opportunity to 
testify today on one of the most important and historically 
overlooked issues in American health care, the health of women 
as they age, particularly during the menopause transition and 
the decades that follow.
 I am Jean Wactawski-Wende, an epidemiologist whose research 
has focused on women's health for more than 40 years. I serve 
as SUNY Distinguished Professor and Dean of the School of 
Public Health and Health Professions at the University at 
Buffalo. Since 1993, I have been a funded investigator in the 
Women's Health Initiative, one of the largest and most 
influential studies of women's health ever conducted.
 WHI enrolled more than 161,000 post-menopausal women across 
the United States to study the effects of hormone therapy, 
diet, and calcium, and vitamin D supplementation on the major 
health outcomes in older women, including heart disease, 
cancer, stroke, osteoporosis, cognition, and mortality.
 Three decades later, nearly 40,000 participants remain 
actively engaged in this study. Their contributions have 
transformed our understanding of women's health and have helped 
millions of women make more informed health decisions. 
Menopause, as you said, Senator Gillibrand, is experienced by 
approximately half our population, and more than one million 
American women enter menopause each year.
 Today, about 64 million women 50 or older are 
postmenopausal, and that number is expected to exceed 80 
million by 2050. These women represent one of the fastest 
growing segments of our population, yet many of their health 
needs remain inadequately studied and addressed. I will 
highlight four priorities that deserve national intention.
 First, we must increase investment in funding research on 
women's health across the lifespan. Women's health research, 
particularly in older women, has been underfunded. We need 
studies that further examine how hormonal changes across the 
lifespan influence healthy longevity. Women are not simply 
smaller versions of men. Biologic differences matter, and 
understanding those differences is essential for developing 
effective prevention and treatment strategies.
 Second, we must address the growing burden of chronic 
disease in aging women. The greatest health challenges facing 
older women include cardiovascular disease, dementia, cancer, 
osteoporosis, and frailty. Women account for the majority of 
Alzheimer's disease cases in the United States, and heart 
disease remains the leading cause of death in women.
 Cancer survivorship is increasing, but many survivors face 
long term effects of treatment that impact independence and 
quality of life. Healthy aging must focus not simply on 
extending life, but on preserving function and independence.
 Third, we must improve education and clinical care for 
women after menopause. Many women report difficulty obtaining 
accurate information and evidence-based care. Menopausal 
symptoms can significantly affect quality of life, yet many 
clinicians receive limited formal training in menopause 
management. Women deserve access to health professionals who 
are informed by the latest science and can provide 
individualized evidence-based health recommendations.
 Fourth, we must recognize the importance of healthy 
behaviors across the life course. Nutrition, physical activity, 
smoking avoidance, sleep health, mental well-being in women at 
younger ages influence their health decades later. Investments 
in prevention beginning early in life can reduce chronic 
disease and frailty at later ages.
 We know that events women experience in pregnancy can be 
associated with related health outcomes as they age. We have 
learned a lot about health and women's health from WHI, and WHI 
opened many new questions. In 1993, I helped to launch WHI when 
I was a new mom of a young daughter. Today, I am the 
grandmother of a 10-month-old granddaughter.
 Like millions of American families, I want the women in her 
generation to have access to the evidence, care, and 
opportunities needed to live long, healthy, and independent 
lives. Health of aging women is one of the greatest public 
health challenges and opportunities of our time.
 Thank you both for your leadership and commitment to 
advancing women's health. I welcome your questions.
 Senator Gillibrand. Thank you. I now want to introduce our 
next witness, Ms. Jennifer Weiss-Wolf. Ms. Weiss-Wolf is--oh, I 
skipped one. I want to introduce our next witnesses, which is 
Dr. Lynne Coslett-Charlton.
 She is a board certified Gynecologist and American College 
of Obstetricians & Gynecologists District III Legislative 
Chair, where she leads regional legislative efforts while 
specializing in minimally invasive and robotic assisted 
surgical procedures.
 Previously, she served as Administrative Chief Resident at 
Pennsylvania Hospital of the University of Pennsylvania and 
currently serves on the American College of Obstetricians and 
Gynecologists.

 STATEMENT OF LYNNE M. COSLETT-CHARLTON, MD, FACOG,

 MSCP, GYNECOLOGIST, AMERICAN COLLEGE OF

 OBSTETRICIANS AND GYNECOLOGISTS,

 PITTSTON, PENNSYLVANIA

 Dr. Coslett-Charlton. Good afternoon. My name is Dr. Lynne 
Coslett-Charlton. I am a private practice gynecologist who has 
been serving my community in Northeastern Pennsylvania for the 
last 27 years.
 I am Fellow of the American College of Obstetricians and 
Gynecologists, or ACOG, which has a membership of more than 
60,000 physicians and partners specializing in and dedicated to 
advancing women's health. Thank you to Senator
 Gillibrand, Senator Scott, and the Special Committee on 
Aging for holding the first hearing on menopause, and your 
efforts to close the gap in menopausal care and improve the 
quality of health for mid-life women.
 OBGYNs like myself care for women throughout their entire 
life cycle, from adolescence through pregnancies, the 
perimenopausal and menopausal transition, and the post-
menopausal years. Over the years, my patients have entrusted me 
through their surgeries, delivering their children, screenings 
for cancer, and contraceptive counseling. Like my colleagues, I 
cherish the relationships with these patients, and I have had 
the privilege now of navigating menopause with many of them.
 Menopause is a normal, expected stage of life marked by the 
permanent end of menstruation, typically occurring around age 
50. Women may spend, like we said, nearly half of their lives 
in the perimenopausal and postmenopausal years. The menopausal 
transition, or perimenopause, typically begins in mid 40's and 
brings significant hormonal changes that can affect a woman's 
health and well-being.
 My patients experience a wide range of symptoms during this 
transition, including hot flashes, vaginal dryness and atrophy, 
difficulty sleeping, altered mood and metabolism, and other 
effects of hormonal change. For some women, these symptoms can 
be debilitating, interfering with daily routine, work, and 
overall quality of life.
 Yet, many women face substantial barriers to obtaining 
timely and effective menopause care for their symptoms. 
Underinvestment of women's health research, physician 
shortages, especially in rural areas, and inadequate health 
insurance coverage can create significant barriers to care, 
which are even more burdensome for underserved and low 
resourced communities.
 Despite the challenges, there are some reasons to be 
optimistic. The FDA's removal of the box warning on estrogen 
therapies was a huge step in the right direction for improving 
access to care. For years, that box warning did not reflect the 
accumulating scientific evidence and discouraged patients and 
clinicians from using an effective treatment. I have seen this 
in my own practice.
 While this move was long overdue, especially for low-dose 
vaginal estrogen treatment with an overall very high safety 
profile, it does have some nuances. Menopause care is not a 
one-size fits all. For some patients, systemic hormone therapy 
may come with an increased risk, emphasizing the importance of 
access to an individualized, thoughtful approach to menopause 
management based on each patient's unique risk factors.
 Moving forward from the seismic change, further research 
into effective treatment options will lead to better and more 
individualized care. By nature, scientific discovery is fluid, 
and so is medical training. When I trained, I was fortunate to 
receive training in menopause care from excellent leaders in 
menopause science and left residency equipped with the tools to 
provide comprehensive care to midlife women. This was pre-WHI. 
More research leads to a better prepared physician workforce. 
In response to new evidence and discoveries, medical education, 
residency training, and continued education programs for 
practicing physicians evolve.
 Increased public awareness and efforts to de-stigmatize 
menopause will lead to better outcomes. I am encouraged by the 
positive improvements in public perception of menopause 
treatment. Celebrity voices and social media have helped to 
normalize menopause and have empowered women to recognize that 
their symptoms are common and treatable.
 Unfortunately, however, social media has also become a 
vehicle for misinformation. Menopause has become big business, 
and many women are turning to influencers rather than trained 
clinicians for advice. Much of my time is spent counseling 
patients about different supplements and unregulated products 
marketed online on different platforms. This is why ACOG and 
other organizations have invested in education to direct 
patients to safe, evidence-based, and medically appropriate 
care.
 Fortunately, there is a path forward. ACOG supports Senator 
Murray's Advancing Menopause Care and Midlife Women's Health 
Act to strengthen and expand federal research, health care 
workforce training, awareness and education efforts, and public 
health promotion and prevention activities.
 Alongside advocacy and opportunities like this hearing, 
together we can make serious progress for my patients and for 
all midlife women. Thank you for having me here today, and I 
look forward to your questions.
 Senator Gillibrand. Thank you. I now would like to 
introduce our next witness, Ms. Jennifer Weiss-Wolf. Ms. Weiss-
Wolf is the Executive Director of NYU Law's Birbaum Women's 
Leadership Center, where she works closely with leaders and 
advocates to pursue policy reforms related to menstruation and 
menopause.
 Previously, she authored a Citizens' Guide to Menopause 
Advocacy and has presented testimony on legal policy before 
Congress, the White House, and State Legislatures across the 
country. You may begin.

 STATEMENT OF JENNIFER WEISS-WOLF, JD, EXECUTIVE

 DIRECTOR, BIRBAUM WOMEN'S LEADERSHIP CENTER AT

 NYU LAW, NEW YORK, NEW YORK

 Ms. Weiss-Wolf. Thank you, Chair Scott, Ranking Member 
Gillibrand, and members of the Committee for convening this 
historic hearing. I am Jennifer Weiss-Wolf, and as you said, my 
work focuses on menstruation, menopause, and the law. It is an 
uncommon sphere of expertise, I know, but these are universal 
experiences for half the population that too often go neglected 
and are deserving of public policy attention.
 I am here today for two reasons. First, to help shine a 
light on the challenges millions of women in the United States 
experience throughout menopause and second, to describe 
policies that can help course correct. Federal agencies like 
the FDA, as well as state governments, including both of your 
home states, are already stepping up.
 None of that is a substitute for the authority of Congress 
and the impact that you can have on moving the needle 
nationwide. I am not a doctor, and I leave the medical 
expertise to my fellow panelists, and I second the jarring 
statistics about lack of research, training, and awareness that 
Senator Gillibrand and Scott have already put forth, but 
numbers can't fully capture the depths of frustration so many 
women encounter.
 I often think of my friend, Dr. Rachel Rubin, who is a 
board-certified urologist here in D.C. at Georgetown and she 
addressed HHS this morning on menopause issues. When Dr. 
Rubin's comatose immunocompromised mother was in immediate 
danger of going into urosepsis, the ICU denied Dr. Rubin's 
request to prescribe vaginal estrogen, incorrectly claiming it 
would cause blood clots.
 After Dr. Rubin eventually secured a prescription, the 
pharmacist refused to dispense it, citing the mere existence of 
its longstanding, inaccurate warning label, which as people 
have mentioned, gratefully the FDA removed and rewrote earlier 
this year. If this is how hard an expert had to fight to get an 
urgent prescription filled, that speaks volumes about what the 
rest of us face.
 What kind of policies can Congress advance to make real-
time changes? I have a few suggestions. Number one would be to 
please fund a modern research agenda. Less than one percent of 
federal research funding goes to menopause and midlife women's 
health. We have not studied women who started taking systemic 
menopausal hormone therapy and perimenopause, or who stayed on 
it continuously from their 50's through their 60's.
 Modern clinical trials that include millennial women and 
Gen X women, diverse racial, ethnic, and geographical 
representation, and data collection and symptom tracking using 
modern technology, all of that is sorely needed. We especially 
deserve to know if there are preventative benefits to our 
chronic brain, bone, and heart health. To that end, women in 
the U.S. are two-thirds of all Alzheimer's cases, yet only 12 
percent of NIH funding for Alzheimer's and related dementia 
research is focused on women.
 Might estrogen support cognitive function? Please don't 
look at the daily headlines, especially this past week, because 
you will see 100 different answers. We deserve gold standard 
clinical trials and I can't help but add that there has been no 
shortage of studies on Viagra's link to lower risk of 
Alzheimer's for men.
 There are three current federal bills that all aim to 
increase research that you should support, the Advancing 
Menopause Care and Midlife Women's Health Act, the Service 
Women and Veterans Menopause Research Act, and the Hormone 
Health Data and Research Act. The second policy priority would 
be to improve education.
 There is consensus that the medical establishment does not 
adequately educate future and current doctors about menopause, 
and that is not just OBGYNs and internists, but includes 
cardiologists, orthopedists, endocrinologists, urologists, 
neurologists, oncologists, all the specialists we may see.
 Congress can intervene by getting behind the Menopause 
Education for Medical Students Act introduced in the House, and 
also pushing Medicare and the Departments of Defense and 
Veterans Affairs, which have control over funding for graduate 
medical education to ensure that menopause education is part of 
the accreditation standard. States have already begun 
addressing this too.
 They have been incentivizing, through their state medical 
boards, to include menopausal in continuing professional 
education for clinicians. The third policy area that requires 
your attention is ensuring affordable, accessible care and 
treatments. Menopause prescriptions can be pricey.
 A monthly supply of systemic hormone therapy will run over 
$100. I am just telling you, mine is $75 with insurance, and 
that is when I can get it, which is few and far between these 
days, thanks to the alarming short supply of estradiol patches 
and I will share, too, that my copay has tripled, because I can 
only get a one-month supply now with the same single copay.
 Non-hormonal treatments for hot flashes are even more 
expensive and not covered by insurance, and these are not 
covered regularly by Medicare or Medicaid. Louisiana was the 
first state to mandate that its own state Medicaid and 
insurance programs in the state mandate menopause treatments, 
and six other states have followed suit. Fifteen years ago, 
Representative Barbara Lee from California introduced the 
Menopausal Hormone Replacement Therapies Act in Congress for 
2011. Please resurrect that.
 I want to just give two quick closing thoughts from the 
advocacy trenches. Please know that there are so many brilliant 
people making massive contributions every day in medicine, in 
innovation, in philanthropy, who are ready to stand with you in 
pushing for bipartisan reforms.
 Second, if you have seen a headline or two or ten saying 
menopause is having a moment, it most definitely is, but it is 
not a moment--it is here to stay and just ask all the loud 
millennials standing behind me. This proud Gen Xer wants to 
thank you for holding this hearing, and I look forward to 
working with you in the future.
 The Chairman. Well, first off, thanks for the witnesses. 
Now, I will introduce our last witness. Dr. Suzanne Fenske is a 
double board certified Gynecologist and Founder of TaraMed, MD, 
a women's health practice in New York City that specializes in 
integrative gynecology, functional medicine, menopause, hormone 
optimization, and longevity medicine.
 She is also a health Ambassador for the U.S. Department of 
Health and Human Services Office on Women's Health and has 
worked to raise awareness of menopause and other women's health 
issues. Thank you for being here. Please begin your testimony.

 STATEMENT OF SUZANNE SILVERMAN FENSKE, MD,

 FACOG, ABOIM, MSCP, DOUBLE BOARD-CERTIFIED

 GYNECOLOGIST, FOUNDER, TARAMD, WOMEN'S HEALTH

 AMBASSADOR, HHS OFFICE ON WOMEN'S

 HEALTH, NEW YORK, NEW YORK

 Dr. Fenske. Thank you, Chairman Scott, and Ranking Member 
Gillibrand, and members of the Senate Special Committee on 
Aging for the opportunity to testify today. I am here both as a 
provider and as a mid-life perimenopausal woman navigating the 
health care system.
 When I ask patients what they hope to get from their care, 
I often hear, I want to feel like myself again. I understand 
this because I felt it myself. The unfamiliar anxiety, 
irritability, insomnia, hot flashes, night sweats, brain fog, 
difficulty doing work, and loss of interest in things I once 
enjoyed.
 Access to appropriate menopause care can help women regain 
that sense of self. That is what is at stake for women we are 
here to represent. I present to advocate for greater investment 
in women's health research, education, and prevention across 
the lifespan, but particularly perimenopause, menopause, and 
the postmenopausal years.
 My own OBGYN education was focused largely on reproductive 
issues and pregnancy. I received very little menopausal 
training in my core curriculum. Every day I see how women's 
concerns, and especially midlife and older women, have fallen 
through the cracks of our health care system.
 Menopause care isn't just about managing symptoms, although 
that is important. Menopause is a turning point, and therefore 
a great window of opportunity for a woman because this phase 
shapes a disease risk and health for the rest of her life. 
Before menopause, a woman's risk of chronic disease is 
typically lower than a man's, but after menopause, her risk 
significantly increases.
 To name just a few, heart disease, hip fractures, and 
urinary sepsis as causes of death in older women. Heart disease 
remains the leading cause of death for women. The loss of 
ovarian hormones with menopause increases the risk for heart 
disease because of changes to body compositions, lipids, 
insulin sensitivity, and blood pressure.
 However, HRT initiated around the time of menopause or 
within 10 years reduces cardiovascular disease, and all-cause 
mortality. Treatment decisions require individualized 
assessment and benefits and risks. Recent outpatient data shows 
HRT use in approximately seven percent of women ages 45 to 54.
 We need to understand how much unmet need remains and 
address the barriers that prevent women from receiving 
appropriate care. Women have almost three times as many hip 
fractures as men. By age 81, one in five women will have a hip 
fracture. By 90, one in two. Twenty percent of those women will 
die within one year. Bone loss accelerates around menopause, 
which occurs on average age about 51.
 Routine bone density screening starts at 65. Early risk 
assessment and prevention are essential. We are missing a huge 
opportunity for prevention, and HRT can prevent bone loss and 
osteoporosis related factors when initiated around menopause. 
While some menopausal symptoms may improve after the menopausal 
transitions complete, other symptoms such as vaginal and 
urinary symptoms, including urinary tract infections, often get 
worse.
 These symptoms are part of the larger condition, genital 
urinary syndrome of menopause, which affects 84 percent of 
women. Recurrent UTIs in older women are particularly dangerous 
because they can lead to sepsis and even death. In a study of 
more than 5,600 women with recurrent UTIs, once vaginal 
estrogen was initiated, there was a 50 percent decline in 
UTI's. To address these gaps, we need greater investment in 
women's health research.
 A National Academy's analysis found that only 8.8 percent 
of NIH grant spending from 2013 to 2023 focused on women's 
health research. One area of research that is desperately 
needed is around breast cancer survivors and the safety and 
efficacy of HRT. These women are often left out of the HRT 
conversation and may miss out on the potential benefits for 
future health and quality of life.
 We also need more education, both for women so they know 
what solutions they have and what to advocate for, and for 
healthcare providers. We currently have a physician shortage 
and desperately need more doctors trained in providing 
menopausal care.
 We also need every other medical specialty to understand 
how menopause affects what they observe and practice every day. 
The Government is in a unique position to help with immediate 
concerns regarding HRT availability. First, we are facing a 
dire shortage of HRT medications, especially patches and daily 
gel use. As more women seek menopausal care and choose HRT, we 
need to meet that demand.
 We cannot push forward without having the availability of 
treatments. Second, we have FDA approved estrogen and 
progesterone, but we desperately need testosterone. It is not 
just about libido. It also supports mood, body composition, and 
energy, to name a few. For some women, it is the peace that can 
finally help them feel like themselves again. As a final 
thought, as we fund more women's health research and train more 
doctors, we need to be thinking about prevention.
 As physicians, we learn how to treat heart disease and 
osteoporosis once diagnosed, but it is a different skill set to 
catch a disease at its earliest stage or even prevent it. How 
we address menopause is an incredible opportunity to improve 
vitality and quality of life for women as they age, which I 
would argue benefits all of society.
 Prevention of disease improves quality of lives, saves 
lives, and lessens economic burden. I would like to thank the 
Senate Committee for this opportunity, and I look forward to 
continued collaboration on this mission to advance women's 
health care.
 The Chairman. Thank you, Dr. Fenske. Let's start with the 
Ranking Member, if you want to start asking questions first.
 Senator Gillibrand. Thank you. I would like to first 
address the barriers to treatment. Despite limited federal 
investment in menopause and midlife women's health research, we 
have made great advancements in treating symptoms of menopause, 
particularly with hormone therapy.
 However, many women still cannot access the care that they 
need. Dr. Coslett-Charlton, from your perspective as a 
clinician, what are the most significant barriers impacting 
women's ability to access treatment, and how does that change 
based on where they live?
 Dr. Coslett-Charlton. In my practice, I treat women with 
all types of health insurance. We definitely see gaps in the 
availability and the coverage with those health insurances. 
Some treatments are covered, other treatments are not. I also 
see these gaps when providing clinical care.
 Much of my day is often spent navigating, this will be 
covered for her, no, this won't be covered for her. I really 
think about my patients and their out of pocket costs because I 
am in a community where, you know, every dollar counts to a lot 
of really hard working women, and the access to barriers with 
insurance coverage is a big problem.
 Second of all, recently, I have been finding in my clinical 
practice that I have to get prior authorization for low-cost, 
FDA approved hormonal therapy. That is a huge burden on the 
practice. I have one nurse that does prior authorizations all 
day.
 These are well-proven treatments and any efforts that 
Congress can make to decrease administrative burden for 
physicians is greatly appreciated.
 Senator Gillibrand. Dr. Silverman Fenske?
 Dr. Fenske. So, so many things. First off, what issues 
remain are that regarding kind of the access, this comes down 
to essentially initially insurance reimbursement, so there is 
not much incentive for physicians to take care of menopausal 
women.
 The way that they are reimbursed from an insurance 
perspective, the hospital system can't support, and the private 
practitioners can't afford to take of menopausal woman for her 
visit because of the amount of money she is reimbursed for that 
visit.
 Senator Gillibrand. Does Medicaid have a better, or 
Medicare have a better reimbursement rate?
 Dr. Fenske. Very low reimbursement rate for those codes--
for those code, yes, so for access to it, and then there comes 
down to the education. When you look across sort of--
unfortunately, you had a wonderful education, but there is no 
guidelines on the education.
 When you are an OBGYN resident, you know that you need a 
minimum of 200 vaginal deliveries to complete your residency. 
There is no mention of how much education you need on 
menopause, so you have these residents graduating not being 
educated. The final issue----
 Senator Gillibrand. Who decides those standards?
 Dr. Fenske. I think it comes down to the ACGME.
 Senator Gillibrand. How many women are on that board?
 Dr. Fenske. I am not certain actually.
 Senator Gillibrand. Dr. Wactawski-Wende, do you have any 
opinion on access?
 Dr. Wactawski-Wende. It is not an area that I research, but 
I do have personal experience and access from family members 
that describe some of the similar things that happen to women, 
not enough health care, not enough trained gynecologists that 
really focus on menopause. I think it really does limit the 
access of women to get the care they need.
 Senator Gillibrand. Thank you. Ms. Weiss-Wolf, from your 
perspective as an advocate and as an author, what are the most 
significant barriers impacting women's ability to access 
treatment, and how does that change based on where they live?
 Ms. Weiss-Wolf. I would say the answer is pretty similar to 
what the physicians on either side said to me, but I hear it 
from patients' point of view, and the frustration that they 
experience.
 I think that the connection of lack of training and lack of 
research leads to a variety of conflicting messages that then 
come down from providers, and people will also be forced to go 
from doctor to doctor if they don't either hear the answer that 
they want to hear, need to hear, or that adequately serves them 
and then that ends up causing additional costs and frustration. 
Oftentimes, they will wind up in the ER. I mean, when you look 
at it from the patient point of view, it is the same problem, 
but it is just how it is experienced. The question about 
geographic, the relevance of geographic location.
 Even while there are certainly care deserts in this 
country, in particular, in the South and the Midwest, even in 
metropolises where there seems to be, you know, plenty of care, 
somebody could still have to wait a month, six months, a year 
for an appointment and one intervention that I think should be 
high on Congress's list is telehealth.
 There are opportunities for menopause care and telehealth 
that I think are unique to the way that that care is provided 
and telehealth could fill a real gap in terms of concentrating 
menopause experts.
 We have to be just very careful that telehealth is 
accessible to all as well, and that there aren't barriers that 
are created by connectivity or insurance otherwise.
 Senator Gillibrand. Thank you, Mr. Chairman.
 The Chairman. Senator Kim.
 Senator Kim. Thank you, Chairman and I just want to thank 
the Ranking Member as well for just your leadership and giving 
us a space to be able to talk about menopause, talk about this 
in a form that often hasn't happened here in the Senate or on 
Capitol Hill as a whole, so your leadership is much 
appreciated. I wanted to just dive into a few different angles 
of this.
 Ms. Weiss-Wolf, I would like to just start with you. Just, 
I am grateful for just the record that you have been able to 
produce of just these testimonials and statements from many 
different women and I guess I wanted to ask you about the 
impact on women's work experience and the challenges on that 
front.
 This is something I am hearing more and more of as my 
generation is growing older, of just women uncertain how to be 
able to balance their careers, especially as we are often 
getting into, hopefully, the heights of our careers in these 
ages but then also understanding, you know, their own 
challenges when it comes to their perimenopause, menopause.
 Some of the difficulties in terms of being able to 
understand how that intersects with it. Also workplaces and 
oftentimes bosses and others maybe not understanding the needs 
that women might be having through those transitions. I want to 
just hear--is that something that you heard about as you were--
as you have been documenting this and engaging with women?
 Are there, you know, certain types of workplace or policy 
changes that you think would be having the greatest impact on 
reducing absenteeism, turnover, wage loss, and other challenges 
that women might be facing?
 Ms. Weiss-Wolf. Thank you for the question, Senator Kim and 
your home State of New Jersey is also a leader in the menopause 
front. The workplace is a really interesting issue to me 
because, yes, it is true that women would be at the prime of 
their leadership in terms of income, in terms of influence, and 
in terms the way that they create, you know, a chain of success 
for others, their mentorship capacity on institutional 
knowledge and skill that they have.
 There have been a wide variety of workplace accommodations 
and benefits that private sector employees have sought to bring 
about. They do see how popular the menopause discourse is, and 
I think want to intervene with some of the best intentions. We 
have also heard the, you know, the economic analysis too about 
what is lost when we don't try to keep women in the workplace 
and support them during this stage.
 I will say that I actually harbor some real concerns about 
those accommodations and those benefits even done with the best 
intentions because right now, we certainly do not have federal 
anti-discrimination protection should somebody choose to take 
their employer up on those benefits.
 Some states, both Illinois and Rhode Island, have actually 
passed laws that both require that the accommodations follow 
suit with how pregnancy accommodations are provided, and 
similarly provide that anti-discrimination protection but 
without that, I am actually very lukewarm about workplace 
benefits and----
 Senator Kim. Because of the lack of federal protection?
 Ms. Weiss-Wolf. Primarily because of the lack of federal 
protection. That would be the biggest reason. The secondary 
reason would be, as my fellow panelists have said, menopause is 
not a one-size fits all circumstance. Most of the reforms are 
focused on very narrow circumstances, whether it is, you know, 
a little bit of flex time or a cooling room opportunity.
 These are things that really would only benefit a very 
small amount of symptoms, a very smaller amount of employees 
who work in an office environment, not the wide variety of ways 
people work today and they certainly don't address the long-
term health consequences that we think about when we think 
about menopause.
 I would far rather see CEOs and business leaders investing 
in the research and investing in the other kinds of systemic 
reforms that we need than putting a few Band-Aids in their 
workplace.
 Senator Kim. That is a helpful perspective. I wanted to 
just turn to Dr. Coslett-Charlton. Something that, again, I 
feel like I am hearing more and more from women of my 
generation, friends, and family, but a real limited 
understanding about perimenopause and just understanding and 
trying to understand, you know, physical, cognitive, emotional 
symptoms.
 I know that they can vary quite wildly, but that transition 
is one that I think has been catching people off guard and 
uncertainty about this. I guess I wanted to ask you, how can we 
raise awareness when it comes to perimenopause, that 
transition, and into full menopause of people who are 
experiencing it so they can try to recognize symptoms and try 
to understand where they might fall within that?
 Dr. Coslett-Charlton. I think one of the things we were 
highlighting was that a lot of social media awareness is out 
there, and menopause is definitely having a moment and one of 
my patients came in the other day, in her mid 20's, and she was 
asking me a lot of questions that had to do with typical 
perimenopausal symptoms, and I thought it was a little bit odd. 
I am like, are you experiencing any of these? She is like, no, 
but perimenopause has a vibe, and I want to be ready.
 The discourse, having hearings like this, having this 
discussion, is really empowering women to take care of 
themselves, and I think that is really wonderful. I think 
channeling that energy by increasing physician workforce, 
increasing patient access to physicians to give them their 
medical advice is really, really important.
 The other thing I want to note is that a lot of times 
perimenopausal symptoms can mimic symptoms of natural disease 
and even though perimenopause is normal-- a lot of women 
deserve a workup.
 I think sometimes the frustrations that patients feel and 
that they don't feel like they are quite being heard, but it 
might be because they are being worked up for more serious 
medical conditions that can have a greater impact on their 
quality of health care and their quality of life.
 I think--you know, I think empowering women is a really 
important thing and educating women, and I really think there 
is a lot of positive discourse happening right now, and that is 
exciting.
 Senator Kim. Yes. No, thank you and as I just wrap up here, 
as someone who is also trying to learn up and have a deeper 
understanding, both personally within my own family, but also 
in the work that we are doing here, I think what I am trying to 
get a deeper sense of is, what is it that is a lack of 
awareness that we need to continue to educate, and what is a 
lack a research, a lack of knowledge and understanding?
 Where do we need to be doing more testing, more research on 
links. You know, I am somebody that has been doing a lot of 
work on cognitive decline. My father has Alzheimer's. A lot of 
issues of dementia. We see, you know, significantly increased 
rates of Alzheimer's and dementia with women. You know, are 
there linkages there in different ways that we need to be 
exploring further when it comes to menopause or other types of 
linkages with other types of ailments?
 You know, that is something that--I am glad we are having 
this hearing because it certainly is focusing it for me as I 
try to think through what is the way in which we need to make 
sure we have the knowledge base to be able to build off from, 
so just very grateful for the Chairman, for the Ranking Member 
for holding this, and we will make sure that we continue to 
followup. Thank you.
 The Chairman. Thank you, Senator Kim. Dr. Fenske, what is 
the link between menopause and longevity, and how can 
treatments like hormone replacement therapy help protect women 
from chronic disease?
 Dr. Fenske. Thank you, Chairman Scott, so the link is that 
basically we know the benefits of, if we use, for example, HRT. 
The benefits in hormone replacement therapy, as I mentioned, 
decrease the risk of cardiovascular disease, diabetes, colon 
cancer, osteoporosis, and there is a 30 percent reduction in 
all-cause mortality if you are on hormone replacement.
 It is innately linked to longevity to be on hormone 
replacement therapy. If women are spending one-third of their 
lives without those hormones and having that impact, we start 
to see those changes as practicing medicine.
 You start to LDL cholesterol start to rise. You start to 
see insulin resistance start to happen, regardless of their 
diet and their exercise. You start to their blood pressure 
start to raise. From a cardiovascular standpoint, the vessels 
start to harden without estrogen. It increases the pliability 
of it, so hormone replacement therapy is linked to longevity.
 The Chairman. You talked about the importance of lifestyle 
interventions like diet, sleep, and exercise. How can these 
help women during this process in addition to medical 
treatment?
 Dr. Fenske. The most important part--obviously I am biased 
in that I am an integrated physician, double boarded, but the 
most important is you have to look at the whole thing, so 
hormone replacement therapy in and of itself is not going to 
completely rectify the picture.
 They have to be educated on proper nutrition, appropriate 
amounts of protein, fiber, and then exercise I think is one of 
the most important things that we can do and that previous 
generations were not as focused on doing. If you want to stay 
out of the nursing homes, we need to exercise and exercise 
starting young and consistently.
 With strength training, cardiovascular, as well as things 
such as yoga, because it improves balance and stretching.
 The Chairman. Why is the type of hormone therapy used so 
important for treating the symptoms of menopause?
 Dr. Fenske. I am so sorry, can you just repeat the 
question?
 The Chairman. Why is the type of hormone therapy used so 
important for treating the symptoms of menopause?
 Dr. Fenske. That is the big question too. When we talk 
about all the studies that we have on hormone replacement 
therapy, we are sort of lumping all these different hormones 
together. It is very nuanced.
 We have to start to differentiate between transdermal 
estrogen versus oral estrogen. A lot of the data in trials we 
have, for example, on potential increased risk of dementia, 
which is questioned--in those trials, that was oral estrogen. 
Oral estrogen is the one that has a small risk of stroke and 
blood clot associated with it, while transdermal estrogen does 
not have that same risk.
 We have to understand the differences between. In addition, 
when we look at progesterone, which is the bioidentical version 
of progesterone, what our bodies naturally produce, versus what 
we used historically, which was progestins, which are synthetic 
progestin, we can compare the two and know that there is 
difference.
 The current studies we have actually are not really looked 
at bio identically progesterone with bioidentical estrogen. 
Most of the trials that we have look at synthetic versions of 
progestins and then we extrapolate that data and assume that it 
is all encompassing.
 Even when I deal with insurance companies and I am denied a 
medication for women, I get calls back from insurance companies 
say, well, why don't you give them vaginal estrogen? I said, 
that is not going to help systemically for them. That is only 
going to help localize symptoms, so even at the level of the 
insurance company, we need to push for education.
 The Chairman. What is the value of seeing a functional 
doctor if you are going through menopause?
 Dr. Fenske. I identify more as integrative, right, because 
that is kind of how I do things. From an integrative 
perspective, when I speak to a woman, I go through all of the 
pillars of their health.
 I focus initially on their nutrition. I will go through 
exactly what they are eating, calculate their ideal protein 
intake. I go to their exercise routine, meeting them where they 
are. You are not going to take somebody who has never exercised 
and give them a stringent exercise plan. Sleep, stress 
management. Stress management is so important during this part, 
especially during this point of life.
 You talk about their sex life, their libido, their orgasms, 
their supplements, their approach to everything, and what they 
want. What are their goals for what they what? It is not just 
about being a physician and saying what you think they should 
be doing. It is important in knowing what their goals are and 
what we want out of their life.
 Really importantly, too, even when we talk about this 
conversation, which is so important, we have to focus on also, 
as mentioned, perimenopause, because that is four to ten years 
ahead of menopause, so even when you are talking about reform 
in regard to businesses and so on to make it easier, you are 
taking about a large portion of life that is going to need to 
have that evaluation.
 The Chairman. Thank you. Ms. Weiss-Wolf, in your testimony, 
you mentioned the FDA's recent decision to remove the black box 
labeling requirement on certain menopause treatments. How has 
the FDA's removal of the black box warning promoted women's 
access to treatment, empowered them to make the best decisions 
for their health?
 Ms. Weiss-Wolf. Thank you. Yes, so I think it is really 
important for people to know that that has been a longstanding 
demand that wasn't new and part of this menopause moment. This 
is--you know, the label was put on all estrogen products, 
including localized vaginal estrogen, after the WHI 
announcement about increased risks of breast cancer and other 
incidents back in 2002, and the label went on in 2003.
 Almost immediately there was pushback, at least certainly 
on the vaginal estrogen, that warning label, that the 
indications that were put on it, probable dementia, blood 
clots, etcetera, did not apply to local vaginal estrogens. 
Again, I am not a doctor, and I am not here to give scientific 
medical evidence, so I will leave that to the folks on either 
side of me but as a matter of practice, it was as scary as a 
cigarette warning label, a skull and crossbones on it.
 The story of patient after patient was not only was it 
sometimes challenging for their doctors to prescribe it because 
they also weren't educated, but the patient would get it and 
look at it once they had it and say, I don't want to take this, 
or their spouse would look at and say why are you taking this, 
and into the trash it would go, so removing that label has been 
a campaign underway for quite some time.
 The FDA denied it in 2018. There was also a lack of 
understanding then of what the product was. They had called it 
low-dose estrogen versus local and there has been a new 
education movement and campaign underway really over the past, 
you know, I would say four or five years.
 Let's Talk Menopause, on which organization I am on the 
board, started an education and citizen petition a couple of 
years ago in 2024 and we were really thrilled that the FDA was 
willing to take it up this past year and held public meetings 
and discussions about it last summer, announced that they would 
be changing the label last November, and then did so this past 
winter. I couldn't answer for the impact the way that 
physicians who see patients could, but it is certainly clear 
that it has changed the conversation.
 The Chairman. Thank you. Dr. Coslett-Charlton, how has the 
way we treat perimenopause and menopause shifted and how has 
this affected how women navigate this time in their lives?
 Dr. Coslett-Charlton. I think I dated myself when I said 
that I had good menopause training pre-WHI, because I aged 
myself with that a little bit. I did have good training, 
because at that time, about 30 percent of women were taking--
were using hormone replacement therapy, and a lot of the 
practitioners and my mentors were leading the cause at the 
time.
 Quickly and abruptly, as I entered private practice, that 
changed, and women became scared. Clinicians became cautious 
and definitely the uptake of hormone replacement therapies 
specifically really, really declined and over time, we began 
treating a lot of symptoms of menopause with other treatments 
that physicians felt comfortable with and that patients felt 
comfortable taking and a lot it was, as you were speaking, the 
perception of--you know, I would give the patients a 
prescription. I documented that--I testified that I have been 
practicing for 27 years. These women, my patients, know me.
 Still, they would go home and read the black box or get 
nervous and not really take the treatment. I think recently, I 
really believe that there has been a lot of attention to 
menopause, more reassurance from smaller studies that have 
given us reassurance on things that organizations like ACOG 
have reviewed the evidence, and thoughtful people and 
researchers way smarter than me have come together and issued 
new guidance where physicians feel comfort in prescribing these 
medications again.
 I have had cardiologists actually send patients to me to 
talk and I think that is really promising to talk about hormone 
replacement therapy and how it can prevent--potentially prevent 
heart disease. I think we need more research on that and 
definitely more clarification.
 We know it can definitely help longevity and bone health in 
women and these are things that I think patients are feeling 
more reassured that they could take the therapies as 
prescribed. They have more confidence in the therapies as 
prescribed, and physicians are also, so a lot of the numbers of 
residency training, I am pretty sure clinically just speaking 
to my colleagues that that information is increasing.
 A lot of things that we learn in residency, as Dr. Fenske 
could attest to also, is a lot our education happens in 
practice. Things that I did 28 years ago, 30 years ago when I 
was a resident, innovation, research, practices change, and as 
lifelong learners and caregivers of women, we need to evolve 
with that.
 I think there has been really great resources to do that. 
ACOG has done a lot of investment. Our recent annual clinical 
and scientific meeting was standing room only for young fellows 
and residents for the menopause track. There is a lot more 
availability for physicians to continue that critical CME to be 
comfortable prescribing these treatments.
 The Chairman. Thank you. Dr. Wactawski-Wende, how can 
treatment lifestyle interventions for women undergoing 
menopause promote healthy aging and aging in place?
 Dr. Wactawski-Wende. Certainly we do know that activity, 
physical activity, getting diets that are high in fiber, low in 
fat, high in protein, all can be great determinants of what 
happens later in life.
 You know, women are complex and have many different health 
outcomes that occur, but some of those preventive measures that 
were already discussed, that I mentioned and some of my 
colleagues, are all important. At this age of menopause, women 
have about a third or more of their lives still to live and it 
is a change hormonally that occurs.
 The menopausal transition occurs, but increases in heart 
disease and cancer and dementia, frailty, osteoporotic fracture 
all occur in that time period. Anything we can do to prevent 
those diseases, I think, is what we should do.
 I want to go back for a second to the importance of 
clinical trials, however, because some of the evidence that we 
are talking about has come from observational studies.
 Clinical trials are the gold standard of evidence, and we 
do not have enough of those trials in women, especially in 
post-menopausal women. WHI was such a trial, and it helped us 
to understand the long-term benefits and risks of hormone 
therapy, specifically conjugated equine estrogen and 
medroxyprogesterone acetate at doses that were common in 1993.
 Now, since WHI's results, the type of formulations and the 
doses have decreased quite a bit, but we have not done the 
clinical trials to look at the health outcomes of those changes 
and I think women deserve to have that done to be able to give 
all our clinicians the evidence to say what are the risks and 
benefits. I am not aware--in WHI heart disease was not 
prevented and in fact, in the first two years of that study, 
there was an increase in heart disease observed.
 There was a similar study done before WHI, the HERS study 
that was looking at secondary prevention of heart disease, and 
in that study as well, in the first two years, taking 
conjugated equine estrogen and medroxyprogesterone acetate 
increased the risk of heart diseases, so there are nuances.
 I do believe lower doses and other formulations may have 
less risky profiles, but we have got to do the science to be 
able to say exactly what those risks and benefits are. I am 
advocating for more clinical trials, more research to help 
women make the most informed decisions.
 The Chairman. Thank you. Let me turn it back over to 
Ranking Member Gillibrand.
 Senator Gillibrand. Thank you, Mr. Chairman. There is a lot 
I want to talk about. We don't have all night. I do want to 
expand on the research. If you could have unlimited dollars to 
do unlimited research, where would you focus your effort, Dr. 
Wactawski-Wende?
 Dr. Wactawski-Wende. I think we are here right now to talk 
about menopause, and I still believe many of these questions 
that I have talked about have not been answered in relation to 
hormone therapy and long-term risks and benefits.
 We already know that hormone therapy is beneficial for 
treatment of menopausal symptoms. It was not the question we 
asked, but should we be taking hormones longer than the 
menopausal transition? What are the risks and benefits of lower 
doses, different formulations? That still is unknown.
 I am a dean of a school of public health, and I do believe 
in prevention, primary, secondary, and tertiary prevention. 
Anything that we can do to help women to live longer and 
healthier lives. The women we talk to in WHI, one of their 
primary concerns is being at home, staying at home as they age, 
having independence.
 Two of the major issues that we are managing and that seem 
to be of concern are mental health and cognition as we age, and 
what we can do to prevent those conditions. We need more 
clinical trials that look at interventions that can delay 
declines in both and also, frailty.
 Senator Gillibrand. I also don't think we have any 
solutions for something that Dr. Silverman Fenske mentioned, 
which is the challenge that older women, particularly women in 
their 70's, 80's and 90's with urinary tract infections, 
because every woman in that age group, they suffer recurring 
infections over and over and again, and they are sometimes 
deadly.
 They go untreated and it is typically given the back of the 
hand by the medical profession with, oh, it is just hygiene. It 
is not. It is something much deeper and more complex because it 
is a constant recurring phenomenon and so, vaginal estrogen may 
be a solution to help that, but are there other solutions? I 
don't know, but I don't think we spend any time researching 
women's health once they hit 70.
 We are begging for dollars when they are in their 40's, and 
their 50's, and their 60's, but I can promise you there is zero 
for 70's and 80's. I do think we need research there. I also 
think we needed research for people who have had breast cancer. 
I do a lot of work to get young women to do their own exams, 
and to lower the age for mammograms because we are seeing more 
women in their 20's and 30's now getting breast cancer when the 
recommendation is you don't start mammograms until you are 40.
 Well, you are dead because you didn't catch it in your 20's 
or 30's, and you weren't educated about how to do that and so, 
we spent a lot of time focusing on breast cancer, so the number 
of women in my cohort who have had breast cancer is shocking of 
just women I know and so, if they aren't able to use patches or 
creams or gels, so they can't have systemic hormones, and they 
can do localized hormones if needed, but what are the solutions 
for them?
 We haven't talked about any solutions outside of hormone 
replacement therapy and if you are talking about X percentage 
of women who can't take that because it increases their breast 
cancer risk, or it makes their breasts denser, or it gives them 
breast pain, these are issues that we are not even mentioning 
and I know a lot of women who suffer from those types of 
things. We have not mentioned the women who have severe 
bleeding, who have fibroids, who have to have hysterectomies.
 Like the amount of medical challenges that hit women going 
through menopause are so numerous, we have barely scratched the 
surface and so, the common understanding of menopausal is, oh, 
you get hot flashes, oh you might not sleep well, oh, yes, deal 
with it, so because we don't talk about the fact that 50 
percent of women can't have sex because it is so painful, that 
is 50 percent of women.
 How much money do we spend investing in Viagra for x 
percent of men who need support? Have we done any investigation 
for 50 percent of women who might need support? Probably not, 
so that is one symptom. I have not heard anything about, what 
do you do with the fibroids and with----
 The Chairman. I think that is important research, by the 
way.
 Senator Gillibrand. Well, you would as a husband, I am sure 
but, and the last point I want to bring up, I want to bring up 
the myriad of symptoms. How do they affect women in the 
workplace? I want talk about women at the height of their 
careers. You are 40. You are just making partner at that big 
law firm.
 You have just gotten your MD. You are starting your 
practice. You are running a small business. You are getting 
your kids off to school and you can finally focus on your 
career. Those years are being undermined by lack of medical 
treatment for the symptoms in the 40's, the symptoms in the 
50's, symptoms in 60's, and into retirement.
 I would like to talk about that, and I would you each from 
your own experience from being a doctor, or a patient advocate, 
or a researcher to tell me what is the economic drag on America 
because we haven't spent enough time focusing on how to treat 
women's health for several decades of their life and during the 
decades of their highest earning potential.
 What are the type of symptoms that are debilitating? What 
happens to women in midlife that derails them? I would like to 
know what percentage of divorces are caused because we just 
didn't treat women's medical needs at the age of 40 and up? 
Probably a very high number.
 How many economic changes have women had to go through 
because of unforeseen divorce, or unforeseen medical problems, 
or breast cancer and not being able to treat these symptoms 
because there is no medicine at all? Please talk about that. I 
want to hear about what is the impact on America because we 
refuse to study women's health after the age of 40? You can 
start, Dr. Silverman.
 Dr. Fenske. Thank you. Thank you for bringing that up. 
Thank you, so of course talk about the benefits in regards to 
health, but yes, 100 percent.
 To really focus in on what the symptoms are and what women 
are experiencing, and what I talked about with the four to ten 
years of perimenopause, so we are not talking about a few 
months of a woman's life that she is going to white-knuckle 
through. The mood symptoms are debilitating for women.
 I have gotten calls from CEOs from a bathroom crying 
hysterically that they are about to go into a meeting, and they 
cannot get through it. The brain fog, the cognition. How many 
women come to me saying, I think I have dementia now. I can't 
remember anything.
 Senator Gillibrand. Anxiety. I have read about anxiety. I 
have read about----
 Dr. Fenske. The anxiety is debilitating. The sleep. They 
are having issues falling asleep. They are waking up. If you 
speak to any woman, 3.00 o'clock in the morning, they are up, 
or early morning wakings. They can't consistently sleep, so 
these things are completely impacting their ability to focus on 
their jobs, their families, their relationships, and just 
navigate through a day.
 Senator Gillibrand. Doctor--or Ms. Weiss-Wolf?
 Ms. Weiss-Wolf. Not doctor. [Laughter.] I am trying to make 
that very clear.
 Senator Gillibrand. Smart woman, Weiss-Wolf.
 [Laughter.]
 Ms. Weiss-Wolf. I will take that. Thank you. I mean, this 
also speaks to the research question, because the question you 
are asking is almost rhetorical. What do we all think that 
means? Of course we know what that means. That means possibly 
taking a step back.
 That means possibly taking a step out. I can share some of 
my own personal experience. I bled so heavily that I couldn't 
get up from a chair in a meeting because I didn't want everyone 
to see that I ruined the chair and my dress. I had rage that 
was so severe, I couldn't even explain it until it went away, 
and then I had to explain it away.
 These were all things that thankfully did not derail my 
career and had I known that there could have been alternatives 
or options or treatment, I would have been thrilled to have 
them. For me, this was years before a menopause moment and 
people were talking about it.
 I just did nothing. I had no doctor who even identified it 
or connected the dots if I raised it. I think in part the 
answer is we have to know this. Thankfully, the Mayo Clinic did 
that study that gives us that $1.8 billion and $26.6 billion 
number so we can throw that around in terms of what the costs 
to the economy are.
 We need so much more investigation that way. Research is 
not just the medical research, but it is these kind of cost 
benefit analyzes, things that make for talking points and 
sticky stats that everybody can't help but listen to.
 Senator Gillibrand. Ms. Weiss-Wolf, did you know anybody 
who had the same symptoms as you to talk to?
 Ms. Weiss-Wolf. No.
 Senator Gillibrand. Because it is not discussed. I just, 
from this stage, discussed many symptoms that no woman would 
even want to discuss with her husband, may not even raise with 
their doctor, certainly isn't going to discuss with their 
community. Women don't want to discuss these things because 
there has been a silence to them, to everyone, to not talk 
about their health.
 That they are told to suffer in silence. I think the lack 
of training with OBGYNs generally has amplified that because 
when they go to talk to their doctor, their doctor might just 
say, well, I don't know, you can try this. You can try that. I 
am not sure. Like the lack of interest, the lack of dedication 
to solving the problem, the lack of knowledge. There is no 
incentive to talk about it but now that I am 59, I have lived 
through perimenopause, menopause, now I am post-menopause, I 
talk to girlfriends all the time. I talk to women all the time.
 Now I have heard of so many symptoms, I can't believe that 
I didn't know about any of them before I got to this position 
in my life and so, that is what this hearing is also about, to 
just say we must talk about the severity of these symptoms, the 
outrage that money isn't being spent, the fact that our doctors 
aren't being trained, and the fact that the American Medical 
Association doesn't seem to care about what their training is 
for their doctors.
 Like, this is all systemic problems, and you guys are all 
part of the solution. Dr. Lynn Cosslett-Charlton, your turn.
 Dr. Coslett-Charlton. I would love to address a few of 
those things. The first, I will go back a little bit, because 
having this conversation is wonderful and we were talking about 
social media and the idea that women can feel more empowered by 
shared stories is wonderful--that they know that there are 
solutions.
 Going back to the breast cancer issue and how to treat 
patients sensitive to breast cancer, I could tell you, not just 
breast cancer patients, there are other patients where 
menopausal hormone therapy may not be appropriate for them and 
for their health and in that patient population, there are a 
lot of effective treatments. None of them are covered without 
major cost sharing.
 There are a lot of problems with access because of that. 
Second, I spent a lot my time for the last 15 years 
volunteering in a health clinic in my community for working 
uninsured women to give them a hand up when they don't have 
insurance at the time and those patients all suffer menopause.
 They all suffer the symptoms. Everything that they would do 
to treat those symptoms is out of pocket and they are not CEOs, 
and they are not physicians like myself, and a lot of them 
aren't educated to the same degree that a lot of us are and it 
isn't just the economic burden for them, but they are worried 
more about putting food on the table, and working, and being 
able to, you know, control their symptoms while they are 
continuing their employment. They are working two, three jobs 
in my patients at my clinic.
 Increasing affordable options, investing. You know, 
fortunately in that clinic there is a lot of private funding. 
They are really--you know, there is a lot of people that fall 
through the cracks, and I anticipate, and I am sure you are 
well aware, next year there is going to be a lot more people 
falling through the cracks that are uninsured, and a lot of 
women that are going to need access to affordable options to 
treat these symptoms so that their lives aren't disrupted.
 Senator Gillibrand. Last, Dr. Wactawski-Wende.
 Dr. Wactawski-Wende. Yes. You brought up 10 or 15 different 
questions.
 Senator Gillibrand. Pick one. Anyone you like. Your choice.
 Dr. Wactawski-Wende. What I would like to say is, in 1985, 
the NIH put forward a study led by Ruth Kirchenstein to look at 
the issues in women's health and at that point in time, the 
report said we were not doing enough research on women. That 
roughly a third of studies even include women.
 There was very little work in the area of menopause. It was 
mostly reproductive. We didn't have trainees with enough 
experience, and we needed to do more to train both clinicians 
and researchers, encourage women to become researchers because 
they might be interested in leading those questions.
 I would argue we are now 35 years later, and we have not 
come all that far and I do believe that some of what you are 
purporting here, more research, more education, empowering 
women with knowledge, and I would say it needs to be rigorous. 
Evidence based knowledge is what we need, and it is not too 
early to start, so, thank you for anything you can do to 
advocate for that for women across the Nation.
 Senator Gillibrand. Thank you all. Thank you, Mr. Chairman.
 The Chairman. Well, I want to thank everyone for being here 
today and participating in this historic hearing. I appreciate 
Ranking Member Gillibrand's leadership on this issue that 
affects so many Americans.
 I look forward to continuing to work with the members on 
the Committee. If any Senators have additional questions for 
the witnesses or statements to be added, the hearing record 
will be open until next Wednesday at 5:00 p.m. Thank you.
 [Whereupon, at 04:40 p.m., the hearing was adjourned.]
=======================================================================

 APPENDIX

=======================================================================

 Prepared Witness Statements

=======================================================================
 
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
=======================================================================

 Questions for the Record

=======================================================================
 
 U.S. Senate Special Committee on Aging

 "Half the Country, Zero Hearings: Meeting the Moment to end the 
 Menopause Care Gap in America"

 September 16, 2026

 Questions for the Record

 Dr. Jean Wactawski-Wende

 Ranking Member Kirsten E. Gillibrand

 Question:

 Informed by 40 years of research in women's health, 
including decades as part of the landmark Women's Health 
Initiative, your testimony highlights the gaps in research for 
chronic diseases and aging.
 What types of additional studies are needed? How will this 
help us develop effective prevention and treatment strategies 
for chronic diseases influenced by menopause?

 Response:

 Women's health research has been understudied for far too 
long. The 1985 Public Health Service (PHS) Task Force on 
Women's Health Issues report, chaired by Dr. Ruth Kirschstein, 
served as a landmark catalyst for changing how we address 
women's health including clinical research that is specific to 
women. The report of the Task Force included recommendations 
on: Promoting a safe and healthful physical and social 
environment; Providing services for the prevention and 
treatment of disease; Conducting research and evaluation; 
Recruiting and training of health care personnel; Educating and 
informing the public and disseminating research information; 
and Designing guidance for legislative and regulatory measures. 
The report revealed that women were routinely excluded from 
major clinical trials and medical research protocols, and that 
animals used in baseline studies were predominantly male. The 
original report can be found at:Https://pmc.ncbi.nlm.nih.gov/
articles/PMC1424718/
#::text=Public%20Health%20Rep,1)%3A73%E2%80%93106.
 Although this report led to the establishment of the Office 
for Research on Women's Health in the early 1990's within the 
NIH and funding for the Women's Health Initiative study, 
progress more generally has been slow. Adequate research 
funding specific to women's health remains a key concern. 
Research studies in women need to include research across the 
lifespan, but particularly in the years leading into menopause 
and the post-menopausal time period, when health risks begin to 
elevate. For example, although we have learned of the risks and 
benefits of a specific type of hormone therapy in the WHI 
(conjugated equine estrogen, CEE, alone or with 
medroxyprogesterone acetate, MPA), newer formulations 
(including transdermal estradiol with or without micronized 
progesterone) and at lower doses are now in predominant use in 
the United States, yet large long-term trials of the risks and 
benefits of these formulations and doses have not been done. A 
new clinical trial in early menopausal women to establish the 
longer-term health risks and benefits of these newer and more 
frequently used formulations is warranted and could be 
conducted with sufficient funding. In addition, clinical trials 
focusing on prevention strategies for conditions that increase 
as women age (heart disease, cancer, osteoporosis, dementia, 
frailty) should be supported by federal funding.
 Prevention strategies not only impact women's lives and can 
reduce morbidity and mortality, but prevention strategies also 
save on related health care costs associated with these 
conditions. We need clinical trials of novel interventions that 
can reduce risk, and also treat or delay these conditions in 
women as they age. Such interventions will help women to remain 
healthier, longer and preferably in their homes, rather than 
facilities requiring high cost to individuals and societies. 
Ultimately, prevention strategies will save on health care and 
caregiving costs.

 Question:

 In what ways does instability in federally funded grants 
impact the ability of researchers like yourself to conduct 
studies and make scientific breakthroughs?

 Response:

 Federal funding through grants and contracts has been the 
key driver in advancing scientific breakthroughs supporting 
health in both women and men over time. Federal funding should 
support research to advance our understanding of the key 
determinants that maintain health throughout our lifespans and 
as we age. Many breakthroughs have come as a result of studies 
funded by the NIH. For example, breast cancer survival is now 
well-over 90% for most women. Survivorship is a direct result 
of early detection and targeted treatments identified in 
studies funded by the NIH. For many cancers and chronic 
diseases of aging, early detection and targeted treatment 
interventions is key. Those breakthroughs came from funding 
from the NIH to extramural scientists. Cardiovascular disease 
(CVD) is the number one killer of women in the United States, 
however many women have died prematurely because their symptoms 
were either not recognized or were misdiagnosed. Symptoms of 
CVD are different in women and men. NIH funded studies have 
helped us in understanding early signs of CVD in women and 
impacted survival, saving lives. NIH-funded clinical trials 
have supported new regimens to prevent and treat many diseases. 
We need more funding for key conditions in women. Without 
federal funding focusing on women, these breakthroughs would 
not have happened. Continued support is needed.
 My own PhD work was supported by funding from the National 
Cancer Institute to study health effects of exposure to 
ionizing radiation in women. That training allowed me to 
develop as a scientist and design and conduct studies that have 
helped to detect and treat diseases in women. NIH funding to 
support the training of upcoming bright scientists to establish 
their careers and scientific discoveries serves all of society. 
Threats to the NIH budget and other federal funding of medical 
and health research impacts all of us. Recent threats to cut 
both intramural and extramural research at the NIH and other 
federal agencies should concern us all. These precious NIH 
dollars need to be protected and in fact, increased, to support 
this critical human health research. The United States has been 
a world-leader in advancing scientific studies to support human 
health. Any threats to funding should concern all of us.

 Question:

 Last April, when the Trump administration indicated its 
intent to terminate the WHI, what happened? Why was there such 
a strong response from the community, and what was the result?

 Response:

 On April 21, 2025, Women's Health Initiative (WHI) 
investigators were informed that the Department of Health and 
Human Services (HHS) would terminate WHI Regional Center (RC) 
contracts at the end of their current fiscal year, September 
2025. I was one of the principal investigators of the Northeast 
WHI regional center. This notice of cancellation came without 
warning or explanation. The WHI investigators were shocked, 
given the remarkable impact WHI had had on women's health.
 There was a tremendous and immediate pushback from the 
public, lawmakers, stakeholders, and the media. Women and 
women's health advocates were very vocal. On April 25, 2025, an 
HHS spokesperson confirmed to the media that the decision to 
cancel the contracts had been rescinded. I personally first 
learned about this reversal from a news media source. WHI 
investigators received official notice that the WHI would be 
allowed to continue on May 6, 2025. Our WHI study participants 
were kept in limbo. At that time point they had been actively 
participating in the WHI study for 30 years.
 Prominent researchers, clinicians, and women's health 
advocates denounced the decision as short-sighted. Women across 
the United States strongly voiced their concerns. Major 
celebrities added their voices to the concerns of the public. 
They warned that defunding the 30-plus-year landmark study 
would severely disrupt ongoing research on cardiovascular 
disease, cancer, osteoporosis, dementia and aging in 
postmenopausal women. WHI was and is the largest and longest 
study of postmenopausal women of its kind. Given that the WHI 
was funded as a response to the 1985 report, any chance of de-
funding this study was a major step backwards in further 
understanding of diseases of aging.
 As a result of this advocacy and public outcry, WHI has 
continued. The WHI study is currently in its 4th extension 
period (September 28, 2020, through January 28, 2027). During 
that period, over 40,000 women continued in the study, 30 years 
after initial enrollment. The women are now 79-110 years of 
age. We continue to have over an 80% response rate from these 
women annually, remarkably 30 years after enrolling. This type 
of commitment of the study participants is unprecedented. 
Hundreds of new scientific discoveries are published annually 
from this rich data source on women's health. Dozens of funded 
ancillary studies are extending the discoveries from the base 
WHI study, looking at factors such as sleep, physical activity, 
diet, mental health, genetics and many of factors on health of 
women as they age.
 One current concern is related to funding for the 5th 
extension study of WHI after January 2028. We are a little over 
one year from our current funding cycle completion. Yet have 
not gotten any formal notification on whether the NIH will fund 
another extension of this landmark study to continue this 
important work. The WHI investigators continue to submit new 
ancillary studies to leverage the data and biologic samples 
available for discovery. Our current focus is on diseases of 
aging in women 80 and older. As noted above, in April 2025 
there was a short period of time when HHS indicated they would 
discontinue WHI funding. The public outrage was immediate and 
strong. As a result, funding was quickly restored. The WHI 
investigators and study participants are waiting eagerly to 
learn of the future plans to fund the WHI continuation beyond 
2028. We would appreciate support from the Senate Special 
Committee on Aging, especially members interested in research 
in women after menopause, for continuation of the 5th extension 
study of WHI. WHI is the most far-reaching study of women after 
menopause ever conducted. Continued funding of the WHI impacts 
all women, as these findings will inform our daughters and 
grandchildren as they age.
 As background, the WHI participants currently provide 
updated data annually on their major health outcomes and 
complete questionnaires on many aspects of their lifestyles, 
experiences and exposures. The WHI also has information from 
CMS (Medicare) related to medical services, procedures and 
medication use through billing records. WHI also maintains a 
biologic specimen bank of blood samples collected at baseline 
enrollment, and over time, to explore mechanistic studies 
underlying medical outcomes and determine biomarkers that can 
help understand how to detect and prevent disease. Ancillary 
studies (i.e. add-on studies) have been funded to expand and 
build onto the WHI database. Examples of currently active 
ancillary studies include studies of stored blood samples that 
look at genetic markers of disease, telomere changes with 
aging, inflammatory biomarkers and much more. WHI women have 
joined two NIH funded studies of muscle mass (and change in 
muscle mass over time), in women after cancer treatment and in 
women with diabetes. Over 5,000 women consented to join these 
studies and provided study samples of blood and urine that help 
us to determine changes in muscle mass age we age. Major 
ancillary studies continue on sleep, physical activity, 
cognition/dementia, stroke biomarkers, health effects following 
cancer therapies, the gut and oral microbiome, inflammation and 
much, much more. Continued NIH funding of WHI is needed to 
support these discoveries. WHI has a far reach, with 
participants coming from ALL 50 states in the U.S.

 Question:

 Sometimes FDA uses temporary regulatory flexibility to 
address a drug shortage. If the agency were to consider a 
supplemental patch supply while U.S. capacity catches up, what 
assurances would physicians and patients need regarding FDA 
review, manufacturing quality, inspections, labeling, and 
ongoing safety monitoring?

 Response:

 I cannot comment on the FDA's review process since it is 
outside of my area of expertise, but I would like to add that 
ready access to any needed medication should be a priority. 
Careful oversight of the U.S. drug supply should be a given.
 On a related point with important relevance, current 
formulations and doses of hormone therapy treatments on the 
market have not been studied for their long-term risks and 
benefits to chronic disease in postmenopausal women in 
randomized clinical trials. In addition, "compounded" 
formulations are not carefully regulated. As background, since 
WHI's hormone therapy trial findings were first released in 
2002 and 2004, the types of formulations and the doses of these 
formulations have changed. Use overall has dropped and many 
women are now taking transdermal estradiol instead of CEE. 
Similarly micronized progesterone is more commonly used than 
MPA. Lower dose options are now available for all these 
formulations. However clinical trials to study the longer-term 
risks and benefits have not been conducted to provide women 
concrete evidence to make their decisions about personal use. 
It is possible that lower doses and other formulations may have 
less risky profiles than those studied in the WHI HT trials, 
however we need to do the necessary randomized clinical trials 
to be able to estimate the risks and benefits of these newer 
formulations and doses.
 I would like to take this opportunity to comment on the 
July 17, 2025 FDA hearing on hormone replacement therapy. The 
FDA panel included individuals with perspectives from a variety 
of disciplines. There were several statements in the 
testimonies that did not adequately describe the trial finding. 
Some statements were incorrect. Many statements were not 
supported by the scientific evidence from randomized clinical 
trials, including several statements made regarding the Women's 
Health Initiative (WHI) study results. There were no 
opportunities during the hearing for public questions or 
comments. Following the hearing, the WHI Steering Committee 
drafted a response to the FDA to correct some of the erroneous 
information that was presented. This response was sent to the 
FDA for their consideration, but to my knowledge, the WHI 
Steering Committee has not received a response to that letter 
from the FDA.
 Below is a copy of that statement which corrects or adds 
context to the information presented to the FDA by panelists. 
This is important information that should be carefully 
considered by the FDA and the Menopause and Aging panel. Some 
comments made by witnesses at the September 16, 2026 Senate 
Special Committee on Aging panel repeated some of the erroneous 
information from the FDA panel. Women need the most accurate 
information, and I am including below the content of the letter 
sent to the FDA panel by the WHI Steering Committee for 
consideration here. See the WHI response below, shaded in light 
gray :
 Women's Health Initiative Comments on FDA Panel on 
Menopause and Hormone Replacement Therapy for Women (Docket: 
FDA: 2025-2589)
 For over 30 years, the Women's Health Initiative (WHI) has 
conducted groundbreaking research on the health of 
postmenopausal women. Prior to WHI, women were often excluded 
from health and medical research, and many pharmaceuticals were 
prescribed for women without rigorous testing for safety or 
efficacy. We are pleased to see renewed interest in the health 
of postmenopausal women, and we urge that any new medical 
recommendations for this age group be based on rigorous 
science.
 During the FDA Expert Panel on Menopausal and Hormone 
Replacement Therapy for Women on July 17, 2025, the results of 
the WHI randomized controlled clinical trials of menopausal 
hormone therapy (MHT) were repeatedly cited in the panelists' 
presentations. In some instances, the WHI findings and their 
interpretation were presented accurately, but in other 
instances panelists' statements and the presentations were 
inaccurate, misleading, or out of context. Additionally, some 
panelists emphasized favorable findings while omitting context, 
creating a partial view of the evidence, particularly for 
combined estrogen plus progestin (CEE+MPA). To inform evidence-
based health care decisions for the nation's women, and in the 
interests of public safety, the FDA needs to make 
recommendations for health care based on the best available 
data, for which the gold standard is the peer reviewed 
summaries of the randomized controlled clinical trials. The FDA 
should not make decisions based on anecdote or misinformation 
presented by persons with known bias or conflicts of interest. 
As representatives of WHI, we herewith provide a summary of the 
WHI peer reviewed trial design and results, together with a 
historical context and commentary where indicated.
 Why were the WHI trials necessary? Premarin (conjugated 
equine estrogens) started being used in the 1940's for the 
relief of menopausal symptoms. To counter a multifold increased 
risk of endometrial cancer in women who had not had a 
hysterectomy a progestogen (medroxyprogesterone acetate) was 
added in the late 1970's. By the 1980's and 1990's MHT was 
increasingly being used for very different reasons: prevention 
of osteoporosis and cardiovascular disease. Though the 
potential risk for breast cancer was recognized, the benefit 
for prevention of coronary heart disease (heart attacks) was 
thought to outweigh the risks of MHT. Whereas earlier use of 
these hormones for treatment of menopausal symptoms was 
primarily in younger women (who were the most likely group to 
have vasomotor symptoms), the later use for prevention of 
osteoporosis and cardiovascular disease shifted the age 
spectrum towards older women (who were most likely to have 
these conditions). According to National Health and Nutrition 
Examination Survey (NHANES) data in 2001-2002 overall 
prevalence of hormone use was 29.5%, with 26.2% prevalence in 
women aged <52, 38.5% at age 52-<65, and 23.2% at age >65 
years.1 Use of hormones for prevention of heart attacks at all 
ages and including women with existing heart disease was 
encouraged by medical society guidelines.
 The enthusiasm for hormones for heart attack prevention was 
driven by promising findings from non-randomized observational 
studies in women free of heart disease as well as in women with 
existing heart disease. These studies predominantly involved 
use of conjugated estrogens alone but also studied use of 
CEE+MPA compared to non-users. Observational studies could be 
biased towards benefit for many reasons, including that women 
using MHT were generally younger, healthier and more likely to 
engage in favorable health behaviors than nonusers, leading to 
confounding by indication and lifestyle.
 However, that is not the entire explanation, since MHT also 
appeared to protect against second heart attacks in women with 
existing disease. Hence, there was a need for large randomized 
controlled trials to settle the issue of prevention of chronic 
disease in both primary prevention in healthy women, and 
secondary prevention in women with existing heart disease. The 
Heart and Estrogen/Progestin Replacement Study (HERS) of 
CEE+MPA tested whether promising observational studies in women 
with existing heart disease would hold up in a rigorous 
clinical trial, and similarly the WHI trials tested whether 
observational studies suggesting benefit in generally healthy 
women would hold up. WHI tested conjugated equine estrogens 
(CEE-alone, in women with a hysterectomy) and CEE+MPA (in women 
with an intact uterus) (the trials are also known as E-alone 
and E+P trials).2-4 Both placebo-controlled trials studied the 
drugs and doses that promised benefit based on observational 
data, and which were the drugs most prescribed at the time. The 
enrollment age range in the WHI trials was 50-79 years so that 
informative data could be generated for both younger and older 
women and to ensure statistical power for the primary outcome 
of coronary heart disease (heart attacks). The WHI trials were 
not designed to test the effects of hormones on vasomotor 
symptoms, a well-established benefit, but contrary to a common 
misconception, women with vasomotor symptoms were enrolled if 
they passed a 1-month placebo run-in period; women currently on 
hormones could be enrolled if in addition they passed a 3-month 
washout period. WHI plans to publish a report specifically 
addressing the trial health outcomes in women with vasomotor 
symptoms (Rossouw et al, in press). WHI randomized 8833 women 
aged 50-59 years in the MHT trials, and one quarter of them, 
reported moderate-severe vasomotor symptoms at baseline, with 
smaller percentages at older ages. the WHI was and still is the 
largest study of MHT in this age-group and hence, much of the 
high-quality data cited by the panel about health outcomes on 
MHT in younger women is derived from the WHI trials.
 What did the trials show? HERS results were announced in 
1998 followed by the results of the WHI trial of CEE+MPA 
stopped early in 2002 (after mean follow-up 5.2 years) 
following a recommendation from the trials' Data Safety and 
Monitoring Board. Both trials showed no benefit for prevention 
of heart attacks and an increased risk of blood clots, with 
significantly higher risks for both heart attacks and blood 
clots in the first 2 years.2,3 The WHI CEE+MPA trial also 
showed an increased risk of stroke and breast cancer, and a 
benefit for fractures and colorectal cancer. In 2004, the WHI 
trial of CEE-alone was also stopped early following a decision 
by the NIH and results published (after mean follow-up 6.8 
years); these showed an increased risk of stroke, reduced risk 
of fractures, and non-significant trends towards reduced risk 
of heart attacks and breast cancer.4 Thus, the trials achieved 
their primary aim of clarifying that menopausal hormone therapy 
did not significantly reduce risk of heart attack. Importantly, 
the risk-benefit profile of E-alone was better than that of 
E+P. Note that the primary results were based on incomplete 
follow-up at the time of early stopping, and that complete 
treatment period follow up of 5.6 years in the CEE+MPA trial 
showed some subtle but important changes, in that the increased 
risk for heart attacks was no longer statistically significant, 
but the increased risk for breast cancer became significant. 
CEE-alone trial results after full follow up of 7.2 years did 
not differ from those of the primary papers.6
 What was the impact of the trials? WHI investigators have 
recently published a comprehensive review of trial results and 
their clinical implications.7 Following publication of the WHI 
CEE+MPA trial results, practice guidelines no longer 
recommended MHT for prevention of heart disease, and the FDA 
applied a black box warning to all MHT products. There was a 
marked reduction in the use of MHT for disease prevention in 
older women but even though use of hormones for menopause 
symptom management was not part of the aims of WHI, the 
findings led to a marked reduction in use of both combined E+P 
and E-alone for relief of vasomotor symptoms in younger women 
and a reduction in training for menopause management at medical 
schools. According the NHANES data, in 2017-2020 prevalence of 
hormone use was down to 4.7% overall, with 9.4% prevalence in 
women aged <52, 4.5% in women aged 52-<65, and 4.3% in women 
aged >65 years.1
 From the outset WHI investigators have recognized that use 
of MHT for treatment of vasomotor symptoms in younger women is 
a reasonable option despite the findings for major health 
outcomes. As early as during the 2002 announcement of the WHI 
trial results, the National Institutes of Health (NIH) included 
in the press release a statement from Dr. Jacques Rossouw, 
Acting Director of the WHI that "Women with a uterus who are 
currently taking estrogen plus progestin should have a serious 
talk with their doctor to see if they should continue it. If 
they are taking this hormone combination for short-term relief 
of symptoms, it may be reasonable to continue since the 
benefits are likely to outweigh the risks. Longer term use or 
use for disease prevention must be re-evaluated given the 
multiple adverse effects noted in WHI." https://
www.sciencedaily.com/releases/2002/07/020710081413.htm. Dr. 
Rossouw also stressed the small absolute risks in individual 
women, though noting that on a population basis the effects 
could be large. Since the WHI trials were stopped in 2002 and 
2004, WHI investigators have published a series of papers to 
clarify risks and benefits by age group and by years since 
menopause. These analyses collected and adjudicated health 
events linked to the intervention for the full treatment period 
of 5.6 years in the CEE+MPA trial and 7.2 years in the CEE-
alone trials, providing more outcomes and follow-up during the 
treatment period than the initial trials' reports. In addition, 
cumulative long-term (intervention plus post-intervention) 
follow-up results describing over 2 decades of information--
particularly relevant for cancer outcomes-have been published. 
The papers confirm that although the relative risks CEE+MPA or 
coronary heart disease (heart attacks) did not differ 
significantly by age, the absolute risks are small in women 
under age 60, while absolute risks are high in women over age 
70, and especially so in older women with persistent vasomotor 
symptoms.5-8 In addition, the influence of MHT on 
cardiovascular outcomes quickly diminished and was not evident 
during postintervention phase, while the influence on breast 
cancer persisted (breast cancer remained significantly 
increased in the CEE+MPA trial, and the previously non-
significant reduction in the CEE-alone trial became 
significant).
 What is the current status of hormone therapy? Over the 
years since release of the WHI findings the Menopause Society 
and others have continued to emphasize that hormone therapy is 
the mainstay of treatment for vasomotor symptoms, and that 
absolute risks of such therapy are low in younger women; 
however, NHANES data indicate that as of 2020 the uptake of 
hormone therapy in younger women has not increased during the 
last 2 decades.1 Oral estrogens are now prescribed less 
frequently than transdermal and intravaginal routes, and among 
oral products CEE and CEE+MPA are less frequently prescribed 
than estradiol and progesterone. Unlike the MHT pharmaceuticals 
tested in WHI, use of other oral MHT pharmaceuticals is not 
supported by the same high-quality data on health effects.
 Issues raised by panel members:

 Timing hypothesis for coronary heart disease and total 
mortality: Several speakers assumed that the timing hypothesis 
was valid, i.e., that hormones started at an early age would 
have lower risks and that the lower risk would carry over into 
subsequent decades. The first part is supported by WHI data 
from the 8,833 women aged 50-59 years enrolled in the trials, 
at least insofar that they have lower absolute risks than older 
women.5-8 The second part, however, remains untested and cannot 
be proven from WHI clinical trial data or observational 
studies; it reflects hope rather than solid scientific 
evidence. The WHI trial data describe initiation of relatively 
short-term (5-7 years) MHT use; it is not feasible to obtain 
longer term trial data capturing initiation at younger ages and 
continued into older ages. Traditional observational studies of 
hormone users can do this, but such studies are not well suited 
to address long term effects because they are prone to several 
biases and confounders that skew results in a favorable 
direction; some of these biases can be overcome with newer 
methods of analysis, which then provide estimates similar to 
those of the trials.9,10
 More specifically, in these newer analyses the trial and 
observational data align in showing an increased risk of heart 
attacks in the first 2 years, and then an attenuation or a 
reversal to benefit in later years. In addition to any 
differences by age or time since menopause at the time of 
initiation, the apparently more favorable overall results in 
the observational studies are due in large part to their longer 
duration, when the initially increased heart attack risks in 
susceptible women are countered by reduced risk in surviving 
women. Long term observational studies have other issues, since 
women who continue hormones for decades are very different from 
non-users in terms of general medical status and health 
behaviors. A very long term very large randomized controlled 
trial in younger women with perfect adherence would be needed 
to answer this question, but such a trial is not feasible. 
Thus, the question of whether initiation at a younger age and 
continued into older ages will result in benefit or harm as 
women and their arteries age remains open. What we do know is 
that risks increase when hormones are initiated at older ages, 
especially so in those with persistent vasomotor symptoms.5,6
 The panel was shown data from the trials in the age group 
50-59 years which show low absolute risks or benefits for a 
number of trial outcomes. The data shown are correct, but 
somewhat misleading. For most health outcomes there was no 
statistical evidence that the MHT relative risks differed by 
age groups. In addition, the materials presented large absolute 
reductions for all fractures and diabetes, but not the large 
absolute increases in gallbladder disease and urinary 
incontinence.6, 11-12 We encourage the FDA to review Manson et 
al. (2013; 2017; 2024) for the influence of MHT across a 
comprehensive range of outcomes, for the full cohort, as well 
as stratified by age group, and to consider the formal 
statistical tests for age-related trends.6-8
 The WHI trial data support short-term use of hormones at 
younger ages because of their low absolute risks, and that is 
sufficient reason to allow for short-term use for their 
traditional indication--relief of vasomotor symptoms. On the 
other hand, WHI does not provide information on long term use 
for heart disease or mortality prevention. Instead, WHI data 
reflect the effects of MHT taken during the 5-7 years of the 
intervention, with prolonged non-intervention follow-up, rather 
than prolonged use. Since initiation of hormones at older ages 
is associated with increased risks, they should not be used to 
prevent heart disease or mortality.
 The panel was informed about a Finnish observational study 
showing that discontinuation of hormone therapy was associated 
with higher risks of cardiac and stroke deaths compared to 
population controls or to women who continued therapy.13 It is 
unclear why this observational study was referenced when we 
have data from a randomized placebo-controlled trial where 
hormones and placebo were simultaneously stopped 
programmatically at the end of the treatment, as opposed to 
unknown reasons why women elected to start and stop in the 
Finnish study. In the WHI trials, the increased risk of 
cardiovascular events was seen during the intervention and 
rapidly diminished during the postintervention. In addition, 
the relative risks for cardiac and stroke mortality were 
neutral during 18 years of follow-up (including 11 years of 
post-trial follow-up).8 In the CEE+MPA trial the risk of heart 
attacks decreased after stopping, and in both the CEE-alone and 
CEE+MPA trials risks of strokes and blood clots decreased after 
stopping.6,7 Thus, the trial findings are not only 
diametrically opposed to those of this particular observational 
study but also indirectly support the causal role of hormones 
during the trial. It would be ironic if observational data were 
now used to counter the very trial evidence designed to address 
the limitations of earlier observational studies. We encourage 
the FDA to review Manson et al. (2013; 2017) for the cumulative 
influence of MHT across a comprehensive range of outcomes, and 
Heiss et al. (2008) and LaCroix et al. (2011) for detailed 
analyses of shorter-term postintervention follow-up.6-7,14-15
 The panel was told that 50,000 women died over 10 years 
because they were denied estrogen at age 50-59 after 
publication of the WHI findings.16 Their estimate was based on 
the difference in absolute mortality rates for women aged 50-59 
years15 and declines in hormone use after the publication, but 
selectively ignores that the estimated reduction in mortality 
during the trial was not statistically significant, as well as 
results of women aged 60-79 that were also randomized in the 
WHI trial.15 We encourage the FDA to review the original 
results reported by LaCroix et al,15 methods used by Sarrel et 
al,61 and WHI's published reply.17 Nonetheless, we agree that 
younger women have lower relative risks of mortality than older 
women,7-8 and that the low absolute risks in younger women, 
particularly in the E-alone trial, do allow for the safe use of 
hormones to treat vasomotor symptoms.
 Timing hypothesis for cognitive function and dementia: The 
panel was shown observational data to support that hormone 
therapy and longer duration of hormone therapy is associated 
with lower risk of neurodegenerative diseases including 
Alzheimer's, supported by rather elegant metabolic studies of 
brain glucose and ketone metabolism, inflammation, and loss of 
white matter across the menopause transition. The hypothesis is 
that the effect of hormones on the brain is dependent on 
whether they are initiated at the peri-menopausal, immediately 
menopausal, or post-menopausal time with benefit at earlier 
periods and harm later. While attractive, the framework is 
partially informed by observational studies which we know to be 
biased due to predominant enrollment of generally healthier 
people (e.g., fewer people who smoke, more people who engage in 
recreational physical activity and have healthy weights). 
Short-term trials of MHT for cognition have given mixed 
results. We do not have long term trials of MHT for dementia 
prevention started in early menopause, but in the WHI trial of 
women aged 50-54 studied 7 years after trial ended there was no 
residual benefit for MHT regarding cognition. In women aged 65 
and older, there was harm for probable dementia/mild cognitive 
impairment during the trials.8 We encourage the FDA to review 
WHI's MHT trial results on cognitive function among younger 
women by Espeland et al, and probable dementia by Shumaker et 
al.18-19
 Breast and other cancers: While the cancer data shown were 
correct, the presentations and discussions were potentially 
misleading. Most importantly, it has been repeatedly mentioned 
that the 2002 CEE+MPA paper only "suggested" an increase in 
breast cancer incidence and that there was no significant 
increase in breast cancer mortality. This statement distorts 
the appropriate statistical inference and ignores the totality 
of the evidence that has been presented over time.
 The CEE+MPA trial was stopped early, on the advice of the 
independent data and safety monitoring board (DSMB), when the 
protocol-specified breast cancer statistic (weighted logrank 
Z=-3.19, 2p=.001) crossed the prespecified monitoring boundary 
for harm (Z=-2.32, 2p=0.01) at mean follow-up time of 5.2 
years.3 This adverse effect emerged approximately 10 years 
earlier than the protocol projected time at which adequate 
power to detect breast cancer harm would be achieved.3 Using 
trial data through the end of blinded intervention (5.6 years), 
the risk of incident invasive breast cancer was significantly 
increased (HR 1.24, weighted logrank P<.001 ), although the 
confidence interval based on a simplified analysis included 1.0 
(ref: PubMed #12824205). An increased risk in breast cancer was 
evident across all age groups, including younger participants 
randomized to CEE+MPA (< 60 y; HR 1.36; 95%CI 1.09 - 1.69)23 
and no statistically significant variation by age group in 
breast cancer outcomes has been seen. These increased risks 
have persisted throughout the post-intervention period; 
published updates reported a 28% increase at 13 years and the 
28% increase at 20 years of cumulative follow-up.6,23
 Additional analyses support a causal interpretation. 
Analyses examining risk by time in study and adherence to study 
pills found that breast cancer risk increased for women in the 
CEE+MPA group with both of these measures of increasing 
exposure to study hormones (Chlebowski, 2009). In another 
analysis that considered duration of exposure, those with 
hormone exposure prior to the trial were at higher risk, 
whereas those without prior use showed no elevation during the 
active intervention period25. The distinction by prior hormone 
use was no longer significant in the 20-year update, as breast 
cancer incidence was significantly elevated with CEE+MPA in 
both those with prior MHT use (HR 1.52; 95%CI 1.16-1.98) and 
those without prior use (HR 1.21; 95%CI 1.05-1.40), directly 
refuting claims that the overall WHI conclusion rests on an 
"anomalous" placebo rate.23
 The statement about no significance for mortality is 
similarly problematic. It is dismissive of real injury to women 
with breast cancer who must undergo arduous therapies including 
chemotherapy, radiation and surgery, with lasting physical and 
emotional consequences, as well as significantly increased all-
cause mortality.23 It also does not acknowledge the fact that 
tumors in the CEE+MPA group were larger, later stage, and more 
likely to involve lymph nodes than those in the placebo group--
findings inconsistent with chance variation, but consistent 
with delayed detection due to increased breast density 
attributable to CEE+MPA.24 Further, while no increase in breast 
cancer mortality was observed at the time the trial was 
stopped, likely because of few deaths observed at that point, 
longer term follow-up found a 96% increase in deaths attributed 
to breast cancer at 11 years mean follow-up (p=0.049) (REF: 
Chlebowski, JAMA 2010).
 During the panel discussion, a speaker claimed that the 
decline in U.S. breast cancer incidence that followed the 
stopping of the WHI CEE+MPA trial was "a statistical change in 
how the data was being analyzed by the group from the CDC." The 
speaker's claim is unsubstantiated and not consistent with SEER 
coding. The report by Ravdin et al. (2007) attributed the sharp 
decline in U.S. breast cancer incidence after 2002 primarily to 
the abrupt reduction in postmenopausal hormone therapy use, 
particularly combined estrogen plus progestin, following the 
early termination of the WHI CEE+MPA trial.27 The analysis was 
peer-reviewed and published in one of the most rigorous medical 
journals. There are no known technical flaws in the 
methodology, NEJM has never retracted, corrected, or revised 
these findings. We encourage the FDA to fully examine the U.S. 
breast cancer incidence following the stopping of the WHI 
trial, and temporal trends reported by Chlebowski et al. (2015; 
2020).23,28
 As accurately noted by one speaker, CEE-alone showed a 
nonsignificant reduction in risk for breast cancer (at 7.1 
years). This reduction persisted and became statistically 
significant in longer term follow-up. Breast cancer mortality 
was also reduced after 20 years.24,26
 We encourage the FDA to fully examine the influence of MHT 
and particularly CEE+MPA on breast cancer incidence, tumor 
characteristics, mammography rates, and breast density, as well 
as the long-term follow-up.22,24
 Other Cancers: The speaker's statements regarding WHI 
portrayal of MHT's association with lung cancer and ovarian 
cancer are inaccurate, as evident in our trial reports.20-22
 The panel was told that neither WHI trial showed an 
increased risk of lung cancer among 50-59 year old women. While 
technically accurate, it is misleading to focus on a specific 
age-group without considering the larger picture. There was no 
statistically significant age trend in either trial so 
conclusions should be based on the entire dataset. CEE+MPA 
significantly increased risk of lung cancer deaths, but not 
incidence20 whereas CEE-alone did not significantly increase 
either lung cancer incidence or death.21 The evidence for WHI's 
MHT trials on lung cancer should be interpreted cautiously, 
however, as this outcome was not a designated endpoint.
 CEE-alone significantly increased risk of ovarian cancer 
incidence by 104% and risk of dying from ovarian cancer by 
179%, while CEE+MPA did not.22 Again, the lack of significant 
interactions by age indicates that the most reliable inference 
is based on the overall results.
 Conclusions
 The WHI trials were primarily designed to study whether MHT 
would reduce heart attacks across all ages spanning 50-79 
years. Additional outcomes that might be affected by MHT were 
studied, including breast cancer as the primary safety 
endpoint. The trials achieved their primary objectives. Results 
showed that MHT did not reduce the risk of heart attacks but 
increased the risk of stroke and blood clots. Breast cancer 
risk was increased, and endometrial cancer decreased in the 
CEE+MPA trial. Fractures were reduced in both trials.
 The WHI trials were not designed to study the effects of 
MHT specifically in younger menopausal women with vasomotor 
symptoms (the main current indication for MHT); nonetheless the 
8,833 women aged 50-59 years represent the largest MHT trial in 
this age group. In this younger age group, the relative risks 
were like those of older age groups in the CEE+MPA trial, 
whereas in the CEE-alone trial women aged 50-59 years had 
significantly lower risks for heart attack, and all-cause 
mortality compared with older age groups. The important take-
home messages from the results in the younger age groups are 
that CEE-alone has a more favorable risk profile, and that in 
both trials the absolute risks were low. The low absolute risk 
in younger women is a sufficient rationale to justify short 
term use of MHT for relief of vasomotor symptoms.
 The panel discussion raised the issue of the black box 
warning on MHT products, particularly topical vaginal products. 
The WHI investigators do not take a position on whether the FDA 
should remove or modify the black box warning on MHT products. 
We recognize that the FDA's boxed warning for all estrogen 
products was rooted in the WHI systemic (oral) hormone trials 
conducted to test chronic disease prevention in women aged 50-
79. However, those randomized trial results do not evaluate and 
may not apply to vaginal estrogen used locally for the 
genitourinary syndrome of menopause or to transdermal MHT for 
vasomotor symptom relief. We encourage the FDA to reevaluate 
whether extrapolating systemic WHI findings to local products 
is appropriate.
 In summary, WHI has contributed enormously valuable 
knowledge to help women make health care decisions. It is 
unknown whether other systemic MHT products such as estradiol 
or progesterone will have similar effects to the conjugated 
equine estrogens and medroxyprogesterone used in the WHI 
trials, because of a lack of similarly large and rigorous 
trials in healthy women. The WHI data remain the best data 
available to inform health care recommendations with regard to 
systemic MHT. The Women's Health Initiative Steering Committee/
www.whi.org
References:

1.Yang L, Toriola AT. Menopausal hormone therapy use among 
postmenopausal women. JAMA Health Forum. 2024;5(9):e243128.14.

2.Hulley S, Grady D, Bush T, et al. Randomized Trial of 
Estrogen Plus Progestin for Secondary Prevention of Coronary 
Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605-
613. doi:10.1001/jama.280.7.605

3.Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group 
for the Women's Health Initiative Investigators. Risks and 
benefits of estrogen plus progestin in healthy postmenopausal 
women: principal results from the Women's Health Initiative 
randomized controlled trial. JAMA. 2002;288(3):321-333.

4.Anderson GL, Limacher M, Assaf AR, et al. Effects of 
conjugated equine estrogen in postmenopausal women with 
hysterectomy: the Women's Health Initiative randomized 
controlled trial. JAMA. 2004; 291(14):1701-1712.

5.Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal 
Hormone Therapy and Risk of Cardiovascular Disease by Age and 
Years Since Menopause. JAMA. 2007;297(13):1465-1477.

6.Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal 
Hormone Therapy and Health Outcomes During the Intervention and 
Extended Post Stopping Phases of the Women's Health Initiative 
Randomized Trials. JAMA. 2013;310(13):1353-1368.

7.Manson, JE, Crandall CJ, Rossouw JE, et al. The Women's 
Health Initiative randomized trials and clinical practice: A 
review. JAMA; 2024;331(20):1748-1760.

8.Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone 
therapy and long-term all-cause and cause-specific mortality: 
The Women's Health Initiative randomized trials. JAMA 
2017;318(10):927-938.

9.Hern n MA, Alonso A, Logan R, et al. Observational studies 
analyzed like randomized experiments: an application to 
postmenopausal hormone therapy and coronary heart disease. 
Epidemiology. 2008;19(6):766-79.

10.Rossouw JE. Reconciling the divergent findings from clinical 
trials and observational studies of menopausal hormone therapy 
for prevention of coronary heart disease. Semin Reprod Med. 
2014;32(6):426-432.

11.Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of 
Estrogen Therapy on Gallbladder Disease. JAMA. 2005;293(3):330-
339.

12.Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of 
Estrogen With and Without Progestin on Urinary Incontinence. 
JAMA. 2005;293(8):935-948.

13.Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et 
al. Increased cardiac and stroke death risk in the first year 
after discontinuation of postmenopausal hormone therapy. 
Menopause 2018;25(4):375-379.

14.Heiss G, Wallace R, Anderson GL, et al. Health Risks and 
Benefits 3 Years After Stopping Randomized Treatment With 
Estrogen and Progestin. JAMA. 2008;299(9):1036-1045.

15.LaCroix AZ, Chlebowski RT, Manson JE, et al. Health Outcomes 
After Stopping Conjugated Equine Estrogens Among Postmenopausal 
Women With Prior Hysterectomy: A Randomized Controlled Trial. 
JAMA. 2011;305(013):1305-1314.

16.Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll 
of estrogen avoidance: an analysis of excess deaths among 
hysterectomized women aged 50 to 59 years. Am J Public Health. 
2013;103(9):1583-8.

17.Prentice, R.L., Manson, J.E., Anderson, G.L., LaCroix, A.Z., 
Shumaker, S.A., Chlebowski, R.T., Howard, B.V., Stefanick, 
M.L., Jackson, R.D., Wactawski-Wende, J. and Rossouw, J.E., 
2013. Women's Health Initiative View of Estrogen Avoidance and 
All-Cause Mortality. American Journal of Public Health, 
103(12), pp.e2-e2

18.Espeland MA, Shumaker SA, Leng I, et al; WHIMSY Study Group. 
Long-term effects on cognitive function of postmenopausal 
hormone therapy prescribed to women aged 50 to 55 years. JAMA 
Intern Med. 2013;173(15):1429-1436

19.Shumaker, Sally A., et al. "Conjugated equine estrogens and 
incidence of probable dementia and mild cognitive impairment in 
postmenopausal women: Women's Health Initiative Memory Study." 
JAMA 291.24 (2004): 2947-2958.

20.Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus 
progestin and lung cancer in postmenopausal women (Women's 
Health Initiative trial): a post-hoc analysis of a randomised 
controlled trial. The Lancet 2009, Volume 374 (9697), 1243 - 
1251.

21.Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer 
among postmenopausal women treated with estrogen alone in the 
women's health initiative randomized trial. J Natl Cancer Inst. 
2010 Sep 22;102(18):1413-21.

22.Chlebowski RT, Aragaki AK, Pan K, et al. Menopausal hormone 
therapy and ovarian and endometrial cancers: Long-term follow-
up of the Women's Health Initiative randomized trials. Journal 
of Clinical Oncology. 2024; 42 (30) suppl https://doi.org/
10.1200/JCO.2024.42.16--suppl.10506

23.Chlebowski RT, Anderson GL, Aragaki AK, et al. Association 
of Menopausal Hormone Therapy With Breast Cancer Incidence and 
Mortality During Long-term Follow-up of the Women's Health 
Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369-
380.

24.Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of 
Estrogen Plus Progestin on Breast Cancer and Mammography in 
Healthy Postmenopausal Women: The Women's Health Initiative 
Randomized Trial. JAMA. 2003;289(24):3243-3253

25.Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone 
therapy and breast cancer risk in the Women's Health Initiative 
randomized trial of estrogen plus progestin. Maturitas. 2006 
Sep 20;55(2):103-15.

26.Stefanick ML, Anderson GL, Margolis KL, et al. Effects of 
Conjugated Equine Estrogens on Breast Cancer and Mammography 
Screening in Postmenopausal Women With Hysterectomy. JAMA. 
2006;295(14):1647-1657.

27.Ravdin, Peter M., et al. "The decrease in breast-cancer 
incidence in 2003 in the United States." New England Journal of 
Medicine 356.16 (2007): 1670-1674.

28.Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, 
Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, 
O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice 
RL. Breast Cancer After Use of Estrogen Plus Progestin and 
Estrogen Alone: Analyses of Data From 2 Women's Health 
Initiative Randomized Clinical Trials. JAMA Oncol. 2015 
Jun;1(3):296-305.

 Question:

 I am pushing to pass the bipartisan Advancing Menopause 
Care and Mid-Life Women's Health Act, led by Senators Murray 
and Murkowski.
 The bill would make a historic investment of $275 million 
dollars into critical biomedical, public health, clinical, and 
translational research through NIH.
 For far too long, mid-life women's health has suffered from 
underinvestment and systemic oversight; this bill provides 
dedicated resources to transform the standard of care.
 In what ways would delivering $275 million in grants over 
five years transform the landscape of research for mid-life 
women, and how might this impact aging women's health outcomes?

 Response:

 In 1985, the NIH put forward a study led by Dr. Ruth 
Kirchenstein to look at research funding for women's health. 
That task force identified that women were sorely under-
represented in major research studies funded by both the NIH 
and private industry. Although some movement was made to 
include women in clinical research, I would argue that 35 years 
later we have not come that far. There is a need for more 
research funding to support research in women at all ages, but 
particularly for the menopausal and post-menopausal time 
frames. The bill proposed by Senators Murray and Murkowski 
would provide funds specific to study these critical issues in 
women's health. I fully support and applaud this Bill and hope 
more initiatives like these will be forthcoming. The funds that 
are proposed would be transformative.

 Question:

 We've heard from each of you about how additional research 
would drive advances in provider training, public education, 
and novel treatments.
 What do you view as the most pressing gap in menopause 
research?

 Response:

 We are an aging society. The demographics are shifting in 
the U.S. with the number of women over age 50 nearly doubling 
in the next two decades. We are unprepared to manage the needs 
of this growing part of our country. Investing in studies that 
can inform women on how to stay healthier, longer are key to 
managing this growth in our aging society. Prevention is key. 
Early detection is key. Promoting resilience is key. As we 
establish additional evidence, we need to train our health 
professionals on the evidence to help them discuss this 
information with their patients. Additional training on 
menopause and associated health concerns needs to be emphasized 
in the training of physicians and other health professionals. 
Last, dissemination from trusted sources directly to women is 
also a key area the federal government invests in and should be 
maintained.

 Senator Raphael Warnock

 Question:

 The Women's Health Initiative is the largest national 
health study focused on the prevention of heart disease, breast 
and colorectal cancer, and osteoporosis in postmenopausal 
women. Since its establishment in 1992 by the National 
Institutes of Health (NIH), WIH has led groundbreaking 
discoveries about menopause and the impact on mid-life women's 
health conditions. Despite its importance, the Trump 
administration attempted to terminate more than four regional 
WHI centers in April 2025. It also recently proposed an 
executive order to grant more decision-making authority to 
political appointees in the NIH grantmaking process, allowing 
the administration to further censor menopause research by 
categorizing it as "diversity, equity, and inclusion."
 How does menopause affect the heart health of middle-aged 
women?

 Response:

 Thank you for these important questions. In my earlier 
response I addressed the temporary funding pause for WHI. I 
also have indicated that we do not know whether WHI will be 
funded for a 5th extension study beyond January 2028. Support 
of WHI by our elected officials and this committee on aging 
would be appreciated.
 You also mentioned a proposed a second question related to 
an executive order, that if implemented, would grant more 
decision-making authority to political appointees in the NIH 
grantmaking process, allowing the administration to further 
censor menopause research by categorizing it as "diversity, 
equity, and inclusion." Historically, NIH funding has been 
determined though a peer-review process, where teams of expert 
scientists in various fields review and score proposals on 
their significance, innovation, methodology, investigator team 
and the research environment of their institutions. This peer 
review process has led to support of the most highly regarded 
science in the world. Historically, those peer reviews were 
then considered by scientists within the NIH, and also 
considered in light of the priorities of the agency, and 
funding decisions were made.
 Having political appointees who may have no scientific 
backgrounds and who are not informed on the state of the 
science, could lead to selection of research that is not making 
the best use of those precious resources. It may also lead to 
politicizing science funding based on beliefs that may not be 
for the greatest societal good. The peer review system has led 
to great discoveries over many decades. It is my belief that 
maintaining this peer review system will ultimately lead to the 
best investments in science to advance health in our 
communities. Leave the decisions on funding to those who know 
it best.
 Last, you inquire about heart health. Cardiovascular 
disease is the number one killer of women in the United States. 
As women age, heart disease increases. As we age, more women 
than men die of heart related conditions in the United States. 
It appears that the increases in heart disease in women begin 
to emerge after the ages at which women reach menopause. One 
belief is that higher estrogen levels in women at younger ages 
prior to menopause may be a protecting factor. That may be 
true. However, many changes occur as women age that also may 
contribute to increasing heart disease (reduced physical 
activity; co-morbidities such as diabetes and hypertension; 
increased inflammation). We need to understand all of these 
factors at more in-depth levels. We can only do that with 
funding to conduct additional studies to better understand 
heart disease (and other conditions) in women as they age.

 Question:

 How many menopause-related NIH grants were terminated since 
the beginning of the Trump administration in January 2025?

 Response:

 I do not know the number of menopause related grants that 
were terminated since the current administration began. I have 
reported that the WHI was terminated for a short period of time 
in April 2025. I have also reported that we remain uncertain if 
future funding will be made available to continue that valuable 
study after January 2028. Any support for continuation of 
funding for the WHI would be appreciated.
 As a dean of the University at Buffalo School of Public 
Health and Health Professions, I am aware that funding for 
critical training grants to support graduate education in 
public health have been cut substantially. We had a training 
grant that is no longer supported by the current 
administration. It would be helpful to understand the extent of 
funding changes that have impacted research funding in women's 
health and also in training grants.
 I do think that a report on grant funding terminations 
should be done. Also looking at funding investments that 
include women and minority human subjects over the past five 
years would be helpful to see. That data should be available 
for every funding cycle.

 Question:

 How would the Trump administration's recent proposal to 
establish a new executive committee reviewing NIH grants affect 
the future of WHI and menopause research at large?

 Response:

 It is not clear what the purpose of such a new executive 
committee would be. The historical use of peer review system 
has generally worked to help the scientific community weigh in 
on the best science. I am not sure that appointees with limited 
depth of knowledge of science and research priorities are best 
suited to make these decisions. More clarity on the role of 
peer review in these proposed changes is needed.
 I would like to note that over the past nearly 2 years, 
there have been many delays in grant reviews and decisions on 
funding that have been very disruptive to the research 
community. These delays have resulted in inefficiencies, with 
investigators needing to re-submit proposals to avoid gaps in 
funding. It also has put a burden on the peer review system, 
because of the lack of timely notifications. In the past 2 
years study sections have been postponed, council review dates 
have been delayed, and those actions have led to delays in 
funding award notices. We need to get this process back on 
track.

 Question:

 What can Congress do to address the gap in medical research 
on the prevention of menopause-related health conditions?

 Response:

 Congress can help address the gaps in medical research on 
the prevention of menopause related conditions by first, 
supporting maintaining or increasing the NIH budget. Supporting 
additional funding by the NIH that focuses on menopause and 
women's health research is key to addressing gaps in our 
knowledge. The proposed bill from Senators Murry and Murkowski. 
"Advancing Menopause Care and Mid-Life Women's Health Act", is 
a very good start to address this issue. There is need to also 
support specific clinical trials to establish risks and 
benefits of certain therapies in women. Although we can learn a 
tremendous amount from observational studies, clinical trials 
are the gold standard of evidence and trials should be demanded 
in instances where we are making clinical recommendations, 
especially related to medications and other interventions with 
potential for risk.
 Of course, this all requires steady and stable funding. It 
also requires maintaining operational practices at the NIH to 
support these advancements. Much more investment into the NIH 
and other similar agencies should be a priority. Support of the 
proposed bill is an essential first step.
 Thank you for the opportunity to respond to these 
questions. Thank you for your leadership focusing on the health 
of women as they (we) age.

 U.S. Senate Special Committee on Aging

 "Half the Country, Zero Hearings: Meeting the Moment to end the 
 Menopause Care Gap in America"

 September 16, 2026

 Questions for the Record

 Dr. Lynne M. Coslett-Charlton

 Ranking Member Kirsten E. Gillibrand

 Question:

 Despite limited federal investment in menopause and mid-
life women's health research, we've made great advancements in 
treating symptoms of menopause, particularly with hormone 
therapy.
 However, many women still cannot access the care they need.
 From your perspective as a clinician, what are the most 
significant barriers impacting women's ability to access 
treatment? How does that change based on where they live?

 Response:

 From my perspective as a physician, one of the biggest 
barriers is simply finding an ob-gyn in their community. 
Physician shortages are a real problem, including in the 
community where I practice, and I urge Congress to act on this 
complex and growing challenge. Cost and insurance coverage are 
another major barrier. Treatment options exist, but women may 
face out-of-pocket costs, inconsistent insurance coverage, or 
prior authorization and step therapy protocols that stand in 
the way of receiving treatment. In addition, until very 
recently there was a black box warning on both low-dose and 
systemic estrogen, meaning that at times, even if a woman was 
prescribed HRT, the warmings on the label discouraged her from 
taking it.

 Question:

 What can Congress do to help address some of these 
barriers, like OB-GYN shortages, estrogen patch shortages, and 
insurance coverage disparities?

 Response:

 Increased investment in the physician workforce and 
addressing the maldistribution of ob-gyns will enable the 
United States to better meet the growing need for menopause 
care. To recruit more physicians to communities with fewer ob-
gyns, we need to make sure the system supports and values the 
care they provide. Current payment structures make it 
challenging for facilities and small private practices to 
operate in rural areas. We also need to address the cost and 
burden of medical liability, which can be a significant barrier 
to practicing obstetrics. Finally, Congress must also invest in 
residency training programs and financial incentives for 
residents to train in rural areas, as data shows that most 
doctors remain in the areas where they train. National Health 
Service Corps is a great example.
 In my office, every day we have a nurse fielding a lot of 
questions from patients looking for patches. The shortage has 
become cumbersome and burdensome as they look to access the 
medication. We have also seen an influx of prior authorization 
requests for the estrogen patch, which further slows down 
access. While there are alternative treatment options to the 
patch, they may not be as affordable. This means that patients 
experience gaps in treatment and wind up in an on again/off 
again cycle with their symptoms. Congress should urge the FDA 
to expediently investigate and address the shortages of 
estradiol products.
 Generally, inconsistent insurance coverage remains a 
significant barrier to accessing care. Varying by payer, 
treatments may be subject to prior authorization, step therapy 
or clinical criteria. Congress should expand insurance coverage 
for menopause treatment, which can help ensure more equitable 
access to affordable care for patients.
 Maintaining Medicaid coverage and adequate reimbursement is 
also essential to ensuring that women have somewhere to go for 
care. Medicaid cuts have a direct impact on whether women can 
get the care they need. When coverage is reduced or lost, women 
may delay or forgo care altogether-not because they don't need 
it, but because they cannot afford it. The result is that women 
suffer needlessly, and conditions that could have been 
addressed earlier can become more serious and more costly to 
treat.

 Question:

 In what ways does peer-to-peer education play an essential 
role in training OB-GYNs?

 Response:

 A significant amount of learning happens after medical 
school-as you see patients, collaborate with your peers and 
mentors, and as a practicing physician, you continue to learn. 
As new science emerges and clinical guidance evolves, 
continuing education plays an important role in ensuring we are 
providing the highest quality, most up-to-date care. I often 
turn to my colleagues, as well as ACOG and other organizations 
that have a number of resources to help clinicians feel well-
equipped and confident to provide this care through every phase 
of their career.

 Question:

 How do ACOG and other organizations contribute to evolving 
continuing medical education, and where would additional 
federal support or coordination be most helpful in accelerating 
that work?

 Response:

 ACOG provides clinical guidance and resources for 
physicians, including continuing medical education 
opportunities such as menopause certificates, and educational 
tracks dedicated to menopause care. ACOG also provides free 
patient-facing web-based resources and a book to help patients 
navigate this transition. Congress can play a role in improving 
public awareness and supporting education on menopause.

 Question:

 In your practice, to what extent does a patient's coverage 
policy dictate their ability to access the treatments they 
need?

 Response:

 Coverage and affordability remain among the most 
significant barriers to menopause care. Even when effective 
treatments exist, patients cannot benefit from them if those 
treatments are unaffordable or difficult to access. Depending 
on the payer, patients may encounter prior authorization 
requirements, step therapy protocols, or other utilization 
management tools that delay or complicate access to care. These 
challenges are particularly acute for patients with complex 
medical histories. Some patients are not good candidates for 
hormone therapy and require alternative treatments, yet those 
nonhormonal options may come with high out-of-pocket costs or 
limited coverage. As a result, the patients who often need 
individualized care the most can face the greatest barriers to 
obtaining it.
 Part of my time is spent providing care to women that are 
under or uninsured. I try to be creative in finding affordable, 
evidence-based options-whether that means choosing a generic 
medication or tailoring treatment to what a patient can 
realistically afford. When women cannot afford care, they may 
delay treatment or turn to providers offering treatments that 
are unproven, expensive, or potentially harmful. We need to 
make sure women have access to affordable, evidence-based care 
before they reach that point.

 Question:

 Many women report that their menopause symptoms are 
dismissed, misdiagnosed, or not adequately addressed in 
clinical settings.
 What barriers do clinicians face in recognizing and 
treating menopause-related symptoms?

 Response:

 I completely understand why patients can feel like they are 
not being heard. It is important that patients get timely 
access to the care they need. When women in their 40s come into 
my exam room with new symptoms, my first responsibility is to 
make sure we are not missing something very serious. 
Perimenopause symptoms can mimic symptoms of other potentially 
life-altering conditions/diseases, so sometimes that means 
testing and ruling out those conditions before we can 
confidently say, "This is perimenopause." That process can take 
time, but we also need to make sure that once serious 
conditions have been ruled out, we recognize perimenopause as a 
likely explanation and help patients understand their options 
for managing their symptoms.
 Conversations about perimenopause and menopause can also 
take time, often longer than the time we have for an annual 
well-woman exam. I want to spend the necessary time with my 
patients, but I see hundreds of patients a week. Workforce 
shortages, inadequate physician reimbursement, and mounting 
administrative burdens limit the amount of time we can spend 
with each patient.

 Question:

 What steps should Congress consider to strengthen menopause 
education and training across medical schools, residency 
programs, and continuing medical education?

 Response:

 While there's plenty we do know about symptoms and how to 
manage them, historical and ongoing underinvestment in research 
in midlife women's health have caused frustrating gaps in our 
understanding of this natural transition. Investing in research 
- better evidence, better understanding of the female biology 
and lifespan-will bolster training and improve care.
 In addition to strengthening and expanding menopause 
research, Senator Murray's Advancing Menopause Care and Mid-
Life Women's Health Act would also help expand health 
professional training. Residency programs are increasingly 
emphasizing menopause care, and additional federal investment 
would give programs the resources needed to expand educational 
opportunities and prepare clinicians to meet growing patient 
demand.

 Question:

 What role can federal student loan incentives play in 
recruiting medical graduates into high-demand subspecialties, 
particularly in underserved communities with gaps in access to 
care?

 Response:

 Federal student loan forgiveness and scholarship programs 
incentivize physicians to train and practice in physician 
workforce shortage areas. Residents come out of medical school 
with mounting student debt, which may impact in which specialty 
and where they choose to practice. These programs reduce the 
significant financial burden our future workforce faces.

 Question:

 The lack of widely available information and public 
education about managing menopause symptoms has allowed bad 
actors to target women online with misinformation.
 This includes promises of "miracle cures" that have not 
been evaluated for effectiveness or regulated by the FDA.
 How should women evaluate claims about products marketed 
for managing menopause symptoms, and where should patients look 
for evidence-based resources on the difference between FDA-
approved therapies versus other remedies not regulated based on 
their safety and effectiveness?

 Response:

 Every day I have conversations with patients about the 
claims they hear, and the products marketed to them online. I 
welcome the conversation and am happy to answer their 
questions. My hope is that everyone can have access to a 
trusted clinician to have these discussions and make informed, 
individualized treatment decisions. Telehealth is a great 
resource and tool for this. But the reality is, not everyone 
has timely access to a clinician. I direct patients to trusted 
resources from organizations such as ACOG and the Menopause 
Society for evidence-based guidance. Especially at a time when 
health misinformation is increasingly prevalent, improved 
public health awareness and access to trusted, evidence-based 
information on menopause and mid-life women's health is 
urgently needed.

 Question:

 As research and access to therapies evolves, how can 
clinicians effectively communicate the benefits, risks, and 
remaining uncertainties in newly developed treatments?

 Response:

 As research and our understanding of menopause continue to 
evolve, clinicians have a responsibility to communicate what we 
know, what we do not yet know, and what the evidence tells us 
about both the benefits and risks of treatment. That starts 
with listening to the individual patient and understanding her 
symptoms, health history, concerns, and goals. There is not a 
one-size-fits-all approach to menopause care, and treatment 
decisions should be based on the best available evidence and an 
informed discussion between the patient and her physician.
 Question:

 I am pushing to pass the bipartisan Advancing Menopause 
Care and Mid-Life Women's Health Act, led by Senators Murray 
and Murkowski. The bill would make a historic investment of 
$275 million into critical biomedical, public health, clinical, 
and translational research through NIH. For far too long, mid-
life women's health has suffered from underinvestment and 
systemic oversight; this bill provides dedicated resources to 
transform the standard of care. How would the workforce 
training provisions included in Senator Murray's bill help to 
make provider education more consistent?

 Response:

 Medical schools and residency programs are increasingly 
emphasizing menopause care within existing educational 
frameworks-- providing resources, like those included in the 
Advancing Menopause Care and Mid-Life Women's Health Act, will 
enable these programs to continue and even expand this work and 
encourage more programs to do the same.

 Question:

 We've heard from each of you about how additional research 
would drive advances in provider training, public education, 
and novel treatments. What do you view as the most pressing gap 
in menopause research?

 Response:

 More research is needed on additional effective treatments, 
and their long-term, later-in-life health benefits. Further 
research into the female biology across the lifespan is sorely 
needed. Bold investment will ensure health care professionals 
like me can connect patients who suffer from significant 
symptoms with affordable, evidence-based treatments, and 
improve my patients' long-term quality of life.

 U.S. Senate Special Committee on Aging

 "Half the Country, Zero Hearings: Meeting the Moment to end the 
 Menopause Care Gap in America"

 September 16, 2026

 Questions for the Record

 Jennifer Weiss-Wolf

 Ranking Member Kirsten E. Gillibrand

 Question:

 Despite limited federal investment in menopause and mid-
life women's health research, we've made great advancements in 
treating symptoms of menopause, particularly with hormone 
therapy. However, many women still cannot access the care they 
need. From your perspective as an advocate and an author, what 
are the most significant barriers impacting women's ability to 
access treatment? How does that change based on where they 
live?

 Response:

 Access to treatment is impeded by the lack of trained 
clinicians, continued confusion around the safety and efficacy 
of FDA approved treatments, and often the cost of treatments 
and care. It is surely harder for women in rural areas and 
those in care deserts; but even for those who live in places 
with more options, wait times and cost can be a barrier.

 Question:

 What can Congress do to help address some of these 
barriers, like OB-GYN shortages, estrogen patch shortages, and 
insurance coverage disparities?

 Response:

 Congress can engage with the Food and Drug Administration 
to ensure meaningful oversight and demand more transparency on 
the part of manufacturers.

 Question:

 In your testimony, you share that a 2025 study found that 
only 26 percent of women have health insurance that covers FDA-
approved menopause treatments and that one in five delayed it 
or passed it up due to financial concerns. Are there 
significant disparities in coverage policies for perimenopause 
and menopause treatments between commercial insurance plans and 
government programs like Medicare and Medicaid?

 Response:

 There is disparity even among private plans as well as 
government programs. Neither Medicaid nor Medicare require that 
menopause treatments be covered. One study shows that medical 
practices that claim to accept Medicaid patients often do not 
serve them well or at all.

 Question:

 If Congress were to change that, how do you think it would 
impact women's ability to access perimenopause and menopause 
care? How would that impact their lives?

 Response:

 Access to treatment that is life-changing - even life-
saving - and should always be a top policy priority. Addressing 
affordability of that treatment vis-a-vis insurance coverage, 
including government programs, is one key way to do so.

 Question:

 In your testimony, you share several stories from women of 
the hundreds recounted to you as part of your advocacy work.
 From your perspective as an advocate for yourself and 
others, what core themes emerge in how menopause symptoms 
impact your health; your work; your family life; and your 
ability to access care? What do you think policymakers, health 
care providers, and the public need to better understand about 
the real-world impact of menopause?
 Response:

 Responding to (a) and (b) together: Menopause is not a 
singular or "one-size-fits-all" experience, and has different 
impacts on each person going through it. For some that might 
mean stress on the family unit; for others that might mean 
greater risk of immediate or long-term health issues; and still 
others it could translate to lost productivity and therefore 
lost wages. All stakeholders need to understand that menopause 
is hormonal and whole-body health - not just a temporary stage 
or something that has a quick fix. We have decades of systemic 
neglect and misinformation to undo. The sooner we start, the 
sooner we begin forging a healthier future.

 Question:

 Dr. Fenske's testimony emphasizes the impact of the 
national physician shortage of primary care providers and 
specialists on menopausal care, like OB-GYNs and geriatricians. 
With the cap on federally funded residency slots limiting our 
training capacity and mounting student debt deterring doctors 
from essential specialties, patients are struggling to find 
providers with specialized training. Patients shouldn't have to 
wait months for appointments, especially when they're in 
serious pain. How would your experience - and the experiences 
of the women you have interviewed - be different if you had 
more access to care and resources offered by clinicians?

 Response:

 See answers above.

 Question:

 Addressing drug shortages is a top priority for this 
committee, and I thank Chairman Scott for his leadership and 
partnership in working to secure our supply chain. Dr. Fenske's 
testimony highlights how the urgent need to address the 
shortage of frontline hormone therapies available to patients, 
particularly transdermal estrogen patches. How are these 
shortages impacting women's lives; women's work; women's 
families; and beyond?

 Response:

 The success women have on this medication is immediately 
undermined by their inability to obtain it and/or the 
extraordinary frustration and time wasted in having to chase it 
down, month after month. For some, the prescription cost 
increases due to copays covering only one moth versus a longer 
supply.

 Question:

 Sometimes FDA uses temporary regulatory flexibility to 
address a drug shortage. If the agency were to consider a 
supplemental patch supply while U.S. capacity catches up, what 
assurances would physicians and patients need regarding FDA 
review, manufacturing quality, inspections, labeling, and 
ongoing safety monitoring?

 Response:

 I cannot envision where a supplemental supply would come 
from; there is no compounded patch equivalent that I am aware 
of. Perhaps more education into alternative transdermal methods 
as well as oral estrogen would be a potential FDA campaign.

 Question:

 Factors like stigma and lack of public awareness continue 
to leave many women without reliable information or support 
during the menopause transition.
 What should a coordinated federal education and awareness 
effort include to ensure women, families, employers, and 
clinicians have accurate, evidence-based information about 
menopause and available care options?

 Response:

 Evidence-based information and resource guide in an easy to 
digest and disseminate medium; I think PSAs are a wonderful 
opportunity for Gen X and Millennials (who were raised on 
them!).

 Question:

 We've heard from each of you about how additional research 
would drive advances in provider training, public education, 
and novel treatments. What do you view as the most pressing gap 
in menopause research?

 Response:

 Fully knowing the preventive, pre-emptive, and/or 
proactive benefits of menopausal hormone therapy to chronic 
brain, bone, and heart health; and

 We need a new, modern version of the Study of Women's 
Health Across the Nation. (SWAN). SWAN is the longest 
longitudinal, multi-racial/ethnic study of women going through 
menopause, launched in 1994 and co-sponsored by NIH's Office of 
Research on Women's Health, the National Institute on Aging, 
the National Institute of Nursing Research, and the National 
Center for Complementary and Alternative Medicine. Preliminary 
ideas for expansion for a SWAN 2.0 would include: new cohorts, 
including Millennials and Gen X women; more equitable racial, 
ethnic and socioeconomic representation; inclusion of Veterans 
and women in military service; expanded geographical 
representation; and more comprehensive symptom tracking using 
modern technology.

 Senator Raphael Warnock

 Question:

 According to the Mayo Clinic, women experiencing menopausal 
symptoms are eight times more likely to report higher turnover, 
absenteeism, and work-related challenges compared to those not 
experiencing symptoms. Often between the ages of 45 and 55, 
many working women also balance taking care of their families 
as part of a sandwich generation while navigating menopause 
themselves.
 Ms. Weiss-Wolf, what is the economic impact of women 
leaving the workforce due to difficulty managing their 
menopause symptoms?

 Response:

 The Mayo Clinic puts numbers on that cost: an estimated 
$1.8 billion in lost work time per year and $26.6 billion 
annually when medical expenses are added, in the U.S. alone.

 Question:

 What unique challenges do women experiencing menopausal 
symptoms face, especially when they serve as sandwich 
caregivers for their family?

 Response:

 Gen X has been the poster child of the "sandwich 
generation" - raising children and caring for aging parent 
simultaneously. Factor in the physical impact of menopause and 
lack of access to care and treatment, and you have women 
shouldering an unmanageable and inequitable load.

 Question:

 How can Congress support women experiencing menopause who 
are in the workforce? What specific arrangements or 
flexibilities could improve working conditions for those who 
also serve as sandwich caregivers?

 Response:

 I really don't think that accommodations are the answer. 
Those I most often see touted miss the mark: some, like desk 
fans and cooling rooms, are mere surface level fixes and have 
short-term value at best, insufficient to meet the decade-plus 
of need that goes well beyond hot flashes; others, like flex-
time and expanded benefits, are important but not likely 
available to women in low-wage or hourly or service jobs. And 
there is no employee in this country guaranteed meaningful 
federal protection under the law from discrimination on the 
basis of menopause.
 Really, we need to make investments in research, education, 
and affordable and accessible treatments. Thos are the reforms 
that will go the longest way in supporting women.

 U.S. Senate Special Committee on Aging

 "Half the Country, Zero Hearings: Meeting the Moment to end the 
 Menopause Care Gap in America"

 September 16, 2026

 Questions for the Record

 Dr. Suzanne Silverman Fenske

 Ranking Member Kirsten E. Gillibrand

 Question:

 In your testimony, you share how your own OB-GYN education 
was focused largely on reproductive issues and pregnancy. You 
state that you received very little menopause training in your 
core curriculum. Now working with women of all ages, how did 
you develop your expertise in the areas of practice where you 
feel your core curriculum training fell short?

 Response:

 I completed training with The Menopause Society and became 
a Menopause Society Certified Practitioner.

 Question:

 In your practices, to what extent does a patient's coverage 
policy dictate their ability to access the treatments they 
need?

 Response:

 I have found that coverage for generic estradiol patch, 
generic estradiol daily gel packet and progesterone have been 
good. Coverage for the products that do not have generics (such 
as evamist, femring, estring, intrarosa) has been poor. With 
the limited availability of patches and gel, this has limited 
access to HRT for many women.

 Question:

 One in ten0 women leave the workforce because of menopause 
symptoms. They're leaving at the peak of their careers and 
taking their experience with them. What are some of the more 
common symptoms of menopause, and how does that impact women at 
work?

 Response:

 There are at least 34 symptoms of perimenopause/menopause. 
Hot flashes/night sweats affect about 75% of women and can 
significantly impact sleep and affect daytime work and comfort 
as well. Sleep disturbances/insomnia are a symptom in and of 
itself with difficulty falling asleep, and/or waking between 2 
am and 4 am or early morning waking. Poor sleep has a direct 
impact on work performance. The psychological symptoms of 
anxiety, depression, mood swings impact ability to perform 
work. The cognitive symptoms of brain fog and difficulty with 
memory and concentration make work performance suboptimal and 
difficult.

 Question:

 What are the most effective workplace supports that 
employers can adopt for their affected workers? What advice 
would you give to managers and human resource professionals?

 Response:

 Connection to appropriate care. This would mean having 
medical insurance that adequately covers menopause care and, 
possibly, having a referring relationship with perimenopause/
menopause telehealth companies that could treat if the woman 
does not currently have a knowledgeable practitioner.

 Question:

 Your testimony emphasizes the impact of the national 
physician shortage of primary care providers and specialists on 
menopausal care, like OB-GYNs and geriatricians.
 With the cap on federally funded residency slots limiting 
our training capacity and mounting student debt deterring 
doctors from essential specialties, patients are struggling to 
find providers with specialized training. Patients shouldn't 
have to wait months for appointments, especially when they're 
in serious pain.
 How would expanding the number of Graduate Medical 
Education slots expand patient access to providers equipped to 
treat their symptoms?

 Response:

 Yes, more slots would allow for more trained practitioners, 
but this is not the sole solution to this issue. As mentioned, 
there is not enough incentive for medical students to go into 
these fields since compensation is low and their student debt 
is high. This has to be readdressed at insurance reimbursement 
level for these appointments. The average commercial 
reimbursement to a physician for seeing a 30+ minutes menopause 
visit is $128. In order to have more physicians in primary care 
and in menopause care, the insurance reimbursement must reflect 
the amount of time and care that physicians put into these 
patients. Salaries for primary care should be higher. Surgical 
specialties earn approximately 90% more than primary care 
physicians. The average debt from medical school is close to a 
quarter of a million dollars. Something has to change to 
encourage medical students to go into primary care. This could 
mean lower medical school costs or high primary care salaries 
(better reimbursement from insurance companies) or the 
government could provide some sort of stipend or loan grievance 
to offset.

 Question:

 Addressing drug shortages is a top priority for this 
committee, and I thank Chairman Scott for his leadership and 
partnership in working to secure our supply chain. Your 
testimony highlights how the urgent need to address the 
shortage of frontline hormone therapies available to patients, 
particularly transdermal estrogen patches. What happens to 
patient care when treatments suddenly become unavailable due to 
a supply shortage?

 Response:

 Thank you for your attention to this urgent matter. Many 
patients have had to discontinue their HRT due to shortage. The 
options that come in generics (such as the patch and the daily 
gel) have been in short supply and many insurance companies 
will not cover alternatives since they are brand. The 
recommendations have been to switch to oral estradiol tablets. 
This issue with this substitution is that oral estrogen confers 
a small but real increased risk of stroke and blood clot. The 
transdermal options do not confer that same risk. Having women 
switch from their transdermal preparations to oral because of 
the shortage would lead to increased cases of stroke and blood 
clot. Many women do not feel comfortable with this increased 
risk. Currently, women are put in the difficult position of 
either discontinuing their HRT which has alleviated their 
symptoms or paying out of pocket or switching to oral 
preparation that have additional risks.

 Question:

 How can the federal government use its oversight 
capabilities to facilitate a sufficient supply of estrogen 
patches for American patients?

 Response:

 The Federal Government is in a unique position to 
facilitate sufficient supply by assisting in removing 
regulatory obstacles, recruit additional manufacturers if 
needed, incentivize domestic manufacturing, meet with 
manufacturers to identify the rate-limiting steps in 
production, expedite manufacturing approvals. In addition, the 
government can require border coverage for FDA-approved 
menopause hormone therapy and limit prior authorizations 
(depending on the insurance company).

 Question:

 Sometimes FDA uses temporary regulatory flexibility to 
address a drug shortage. If the agency were to consider a 
supplemental patch supply while U.S. capacity catches up, what 
assurances would physicians and patients need regarding FDA 
review, manufacturing quality, inspections, labeling, and 
ongoing safety monitoring?

 Response:

 Sourcing from a country that meets or exceeds FDA's current 
standards and assurances that the supply will be adequate until 
US capacity catches up.

 Question:

 Factors like stigma and lack of public awareness continue 
to leave many women without reliable information or support 
during the menopause transition. As a Women's Health Ambassador 
for the HHS Office on Women's Health, how does the quality of 
available information about hormones, lifestyle, and overall 
health impact outcomes for patients?
 Response:

 Unfortunately there is a reliance on social media 
influencers, artificial intelligence and unqualified providers. 
This has led to misinformation, delay in treatment, fear and 
use of "snake oil" solutions.

 Question:

 The lack of widely available information and public 
education about managing menopause symptoms has allowed bad 
actors to target women online with misinformation. This 
includes promises of "miracle cures" that have not been 
evaluated for effectiveness or regulated by the FDA. How should 
women evaluate claims about products marketed for managing 
menopause symptoms, and where should patients look for 
evidence-based resources on the difference between FDA-approved 
therapies versus other remedies not regulated based on their 
safety and effectiveness?

 Response:

 The government should create an information page on 
menopause that reviews the data for FDA approved therapies as 
well as supplements and lifestyle intervention stating what 
data exists and when data is lacking.

 Question:

 As research and access to therapies evolves, how can 
clinicians effectively communicate the benefits, risks, and 
remaining uncertainties in newly developed treatments?

 Response:

 For primary care physicians and OBGYNs, there needs to be a 
conversation with women at their annual examinations, perhaps 
at the age of 40. We are instructed to discuss nutrition, 
exercise, need for mammograms, contraception as part of our 
annuals, but there should be an expectation of a perimenopause/
menopause conversation at age 40. While for some women this 
will be after their symptoms have started, on average, this 
would cover most women ahead of the symptoms.

 Question:

 We've heard how additional research would drive advances in 
provider training, public education, and novel treatments. What 
do you view as the most pressing gap in menopause research?

 Response:

 Lack of a large, adequately powered randomized trial of 
transdermal estradiol plus oral progesterone assessing long-
term breast cancer incidence and mortality, myocardial 
infarction, stroke and blood clot, all cause mortality and 
cardiovascular mortality.
=======================================================================

 Statements for the Record

=======================================================================
[GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 

 [all]